Efficacy of olfactory ensheathing cells to support regeneration after spinal cord injury	1
Efficacy	1
olfactory ensheathing cells	13
regeneration	52
spinal cord injury	71
method of culture preparation Liudmila N. Novikova a , Sergei Lobov a , Mikael Wiberg a , b , Lev N. Novikov a , a Department of Integrative Medical Biology , Section of Anatomy , Umeå University , SE-901 87 Umeå , Sweden b Department of Surgical and Perioperative Science , Section of Hand and Plastic Surgery , Umeå University , SE-901 87 Umeå , Sweden	107
method	107
culture preparation Liudmila N. Novikova a , Sergei Lobov a , Mikael Wiberg a , b , Lev N. Novikov a , a Department of Integrative Medical Biology , Section of Anatomy , Umeå University , SE-901 87 Umeå , Sweden b Department of Surgical and Perioperative Science , Section of Hand and Plastic Surgery , Umeå University , SE-901 87 Umeå , Sweden	117
culture preparation Liudmila N.	117
Novikova a , Sergei Lobov a , Mikael Wiberg a , b , Lev N. Novikov a , a Department of Integrative Medical Biology , Section of Anatomy , Umeå University , SE-901 87 Umeå , Sweden b Department of Surgical and Perioperative Science ,	150
Novikova a	150
Sergei Lobov a	162
Sergei Lobov	162
a	175
Mikael Wiberg a	178
Mikael Wiberg	178
a	192
b	194
Lev N. Novikov a	197
Lev N. Novikov	197
a	212
a Department of Integrative Medical Biology	216
a Department	216
Integrative Medical Biology	232
Section of Anatomy	261
Section	261
Anatomy	272
Umeå University	281
SE-901 87 Umeå	298
Sweden b Department of Surgical and Perioperative Science	314
Sweden b Department	314
Surgical and Perioperative Science	337
Section of Hand	373
Section	373
Hand	384
Plastic Surgery , Umeå University , SE-901 87 Umeå , Sweden	393
Plastic Surgery	393
Umeå University	410
SE-901 87 Umeå	427
Sweden	443
a b	452
t r a c t Olfactory ensheathing cells -LRB- OEC -RRB- have been shown to stimulate regeneration , myelination and functional recovery in different spinal cord injury models	458
t r	458
a c t Olfactory ensheathing cells -LRB- OEC -RRB-	462
a c t Olfactory ensheathing cells	462
a c t	462
Olfactory ensheathing cells	468
OEC	497
regeneration , myelination and functional recovery	531
different spinal cord injury models	584
recent reports from several laboratories	630
recent reports	630
several laboratories	650
this treatment strategy	687
The discrepancy in results	712
The discrepancy	712
results	731
many factors including variations in culture protocols	762
many factors	762
variations in culture protocols	785
variations	785
culture protocols	799
The present study	818
the differences in culture preparation	857
the differences	857
culture preparation	876
neuroprotective and growth-promoting effects of OEC	912
neuroprotective and growth-promoting effects	912
OEC	960
transplantation	970
the injured spinal cord	991
Primary OEC cultures	1016
method of differential cell adhesion -LRB- a-OEC -RRB-	1057
method	1057
differential cell adhesion -LRB- a-OEC -RRB-	1067
differential cell adhesion	1067
a-OEC	1095
immunomagnetic beads -LRB- b-OEC -RRB-	1120
immunomagnetic beads	1120
b-OEC	1142
cervical C4 hemisection in adult rats	1156
cervical C4 hemisection	1156
adult rats	1183
short-term -LRB- 3 weeks -RRB- or long-term -LRB- 7 weeks -RRB- cultured OEC	1195
short-term -LRB- 3 weeks -RRB-	1195
short-term	1195
3 weeks	1207
long-term -LRB- 7 weeks -RRB- cultured OEC	1219
long-term -LRB- 7 weeks -RRB-	1219
long-term	1219
7 weeks	1230
OEC	1248
the lateral funiculus at 1 mm rostral and caudal	1275
the lateral funiculus	1275
1 mm rostral and caudal	1300
1 mm rostral	1300
caudal	1317
the transection site	1327
3	1352
8 weeks after transplantation , labeled OEC	1354
8 weeks	1354
transplantation , labeled OEC	1368
transplantation	1368
OEC	1393
the injection sites	1418
the trauma zone	1445
Short-term cultured a-OEC	1462
Short-term	1462
a-OEC	1482
regrowth of rubrospinal , raphaespinal and CGRP-positive fibers	1498
regrowth	1498
rubrospinal , raphaespinal and CGRP-positive fibers	1510
retrograde degeneration	1577
the red nucleus	1604
Shortterm cultured b-OEC	1621
Shortterm	1621
b-OEC	1640
axonal regrowth	1664
the density of rubrospinal axons	1694
the density	1694
rubrospinal axons	1709
the dorsolateral funiculus	1734
significant neuroprotection	1774
axotomized rubrospinal neurons	1806
addition	1841
short-term cultured OEC	1851
short-term	1851
OEC	1871
rubrospinal terminals	1899
contrast	1925
long-term	1935
OEC	1954
axonal growth	1975
retrograde cell death	2003
The results	2026
the age of OEC in culture and the method of cell purification	2051
the age	2051
OEC in culture and the method of cell purification	2062
OEC in culture	2062
OEC	2062
culture	2069
the method of cell purification	2081
the method	2081
cell purification	2095
the efficacy of OEC	2126
the efficacy	2126
OEC	2142
neuronal survival and regeneration	2157
spinal cord injury	2198
This article	2218
part of a Special Issue entitled	2234
part	2234
a Special Issue entitled	2242
a Special Issue	2242
olfactory ensheathing glia and their prospect for nervous system repair	2282
olfactory ensheathing glia	2282
their prospect for nervous system repair	2313
their prospect	2313
nervous system repair	2332
Introduction	2356
the adultmammalian spinal cord	2372
damage to nervefibers	2404
damage	2404
nervefibers	2414
nearly complete failure of the severed axons to regenerate	2437
nearly complete failure	2437
the severed axons to regenerate	2464
Pathology of the spinal injury	2497
Pathology	2497
the spinal injury	2510
the initial mechanical insult	2554
secondary processes including ischemia and cell death	2597
secondary processes	2597
ischemia and cell death	2627
cyst formation and enlargement of the trauma zone	2678
cyst formation and enlargement	2678
the trauma zone	2712
Cytokines , free radicals and nitric oxide generated by microglia	2729
Cytokines	2729
free radicals	2740
nitric oxide generated by microglia	2758
nitric oxide	2758
microglia	2784
reactive astrocytes	2804
proteoglycans	2835
glial scar -LRB- Busch et al. , 2010 ; Fitch and Silver , 2008 -RRB-	2861
glial scar	2861
Busch	2873
et al. , 2010 ; Fitch and Silver , 2008	2879
et al.	2879
2010 ; Fitch and Silver	2887
2010	2887
Fitch and Silver	2893
2008	2911
addition	2921
retrograde degeneration	2931
the lesioned spinal tracts	2965
Deumens et al. , 2005	2993
Deumens	2993
et al.	3001
2005	3009
axons	3024
inhibitory nature of myelin and the glial scar	3045
inhibitory nature	3045
myelin and the glial scar	3066
myelin	3066
the glial scar	3077
little functional recovery -LRB- Boulenguez and Vinay , 2009 ; Bunge , 2008 ; Tetzlaff et al. , 2010 -RRB-	3128
little functional recovery	3128
Boulenguez and Vinay , 2009 ; Bunge , 2008 ; Tetzlaff et al. , 2010	3156
Boulenguez and Vinay	3156
Boulenguez	3156
Vinay	3171
2009 ; Bunge	3178
2009	3178
Bunge	3184
2008 ; Tetzlaff et al. , 2010	3191
2008	3191
Tetzlaff et al. , 2010	3197
Tetzlaff	3197
et al. , 2010	3206
et al.	3206
2010	3214
regeneration	3232
spinal cord injury	3251
several challenging objectives	3271
inhibitory signals	3334
the trauma zone	3356
secondary degeneration , scarring and cavitation	3382
secondary degeneration	3382
scarring	3406
cavitation	3419
spinal cord tissue gaps	3440
axonal growth	3487
the lesion site	3508
Experimental data	3525
different treatment strategies including modification of inhibitory extracellular matrix molecules , transplants of embryonic nervous tissue and glial cells , bridging nerve grafts and neurotrophic factors	3557
different treatment strategies	3557
modification of inhibitory extracellular matrix molecules , transplants of embryonic nervous tissue and glial cells , bridging nerve grafts and neurotrophic factors	3598
modification	3598
inhibitory extracellular matrix molecules , transplants of embryonic nervous tissue and glial cells ,	3614
inhibitory extracellular matrix molecules	3614
transplants of embryonic nervous tissue and glial cells	3657
transplants	3657
embryonic nervous tissue and glial cells	3672
embryonic nervous tissue	3672
glial cells	3701
nerve grafts and neurotrophic factors	3723
nerve grafts	3723
neurotrophic factors	3740
principle	3771
regeneration of injured central nerve tracts -LRB- Bunge , 2008 ; Fortun et al. , 2009 ; Kocsis et al. , 2009 ; Lu and Tuszynski , 2008 ; Tetzlaff et al. , 2010 -RRB-	3792
regeneration	3792
injured central nerve tracts -LRB- Bunge , 2008 ; Fortun et al. , 2009 ; Kocsis et al. , 2009 ; Lu and Tuszynski , 2008 ; Tetzlaff et al. , 2010 -RRB-	3808
injured central nerve tracts	3808
Bunge , 2008 ; Fortun et al. , 2009 ; Kocsis et al. , 2009 ; Lu and Tuszynski , 2008 ; Tetzlaff et al. , 2010	3838
Bunge	3838
2008 ; Fortun et al. , 2009 ; Kocsis et al. , 2009 ; Lu and Tuszynski , 2008 ; Tetzlaff et al.	3845
2008	3845
Fortun et al. , 2009 ; Kocsis et al. , 2009 ; Lu and Tuszynski , 2008 ; Tetzlaff et al.	3851
Fortun	3851
et al. , 2009 ; Kocsis et al. , 2009 ; Lu and Tuszynski , 2008 ; Tetzlaff et al.	3858
et al. , 2009	3858
et al.	3858
2009	3866
Kocsis et al. , 2009	3872
Kocsis	3872
et al. , 2009	3879
et al.	3879
2009	3887
Lu and Tuszynski , 2008	3893
Lu and Tuszynski	3893
2008	3911
Tetzlaff et al.	3917
Tetzlaff	3917
et al.	3926
2010	3934
promising effects on axonal regeneration and neuronal survival after spinal cord injury	3952
promising effects	3952
axonal regeneration and neuronal survival after spinal cord injury	3973
axonal regeneration and neuronal survival	3973
spinal cord injury	4021
transplantation of a certain glial cell type , the olfactory ensheathing cells -LRB- OEC -RRB- -LRB- Fouad et al. , 2009a ; Franssen et al. , 2007 ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 ; Raisman et al. , 2011 ; Richter and Roskams , 2008 -RRB-	4065
transplantation	4065
a certain glial cell type , the olfactory ensheathing cells -LRB- OEC -RRB- -LRB- Fouad et al. , 2009a ; Franssen et al. , 2007 ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 ; Raisman et al. , 2011 ; Richter and Roskams , 2008 -RRB-	4084
a certain glial cell type	4084
the olfactory ensheathing cells -LRB- OEC -RRB- -LRB- Fouad et al. , 2009a ; Franssen et al. , 2007 ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 ; Raisman et al. , 2011 ; Richter and Roskams , 2008 -RRB-	4111
the olfactory ensheathing cells -LRB- OEC -RRB-	4111
the olfactory ensheathing cells	4111
OEC	4144
Fouad et al. , 2009a ; Franssen et al. , 2007 ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 ; Raisman et al. , 2011 ; Richter and Roskams , 2008	4150
Fouad	4150
et al. , 2009a ; Franssen et al. , 2007 ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 ; Raisman et al. , 2011 ; Richter and Roskams , 2008	4156
et al. , 2009a	4156
et al.	4156
2009a	4164
Franssen et al. , 2007	4171
Franssen	4171
et al. , 2007	4180
et al.	4180
2007	4188
Kocsis et al. , 2009	4194
Kocsis	4194
et al. , 2009	4201
et al.	4201
2009	4209
Lindsay et al. , 2010	4215
Lindsay	4215
et al. , 2010	4223
et al.	4223
2010	4231
Munoz-Quiles et al. , 2009	4237
Munoz-Quiles	4237
et al. , 2009	4250
et al.	4250
2009	4258
Radtke and Wewetzer , 2009	4264
Radtke and Wewetzer	4264
2009	4285
Raisman et al. , 2011	4291
Raisman	4291
et al. , 2011	4299
et al.	4299
2011	4307
Richter and Roskams , 2008	4313
Richter and Roskams	4313
2008	4334
the mechanisms of growth-promoting and neuroprotective effects of OEC	4350
the mechanisms	4350
growth-promoting and neuroprotective effects of OEC	4368
growth-promoting and neuroprotective effects	4368
OEC	4416
It	4451
OEC	4474
various neurotrophic factors -LRB- Lipson et al. , 2003 ; Pastrana et al. , 2007 -RRB-	4486
various neurotrophic factors	4486
Lipson	4516
et al. , 2003 ; Pastrana et al. , 2007	4523
et al.	4523
2003 ; Pastrana et al.	4531
2003	4531
Pastrana et al.	4537
Pastrana	4537
et al.	4546
2007	4554
proteins which indirectly stimulate Schwann cells to support neurite outgrowth	4569
proteins	4569
Schwann cells	4605
neurite outgrowth	4630
spinal cord repair -LRB- Au et al. , 2007 -RRB-	4660
spinal cord repair	4660
Au	4680
et al. , 2007	4683
et al.	4683
2007	4691
contrast to Schwann cells	4705
contrast	4705
Schwann cells	4717
astrocytes	4749
their hypertrophy -LRB- Lakatos et al. , 2000 ; Santos-Silva et al. , 2007 -RRB-	4777
their hypertrophy	4777
Lakatos	4796
et al. , 2000 ; Santos-Silva et al. , 2007	4804
et al.	4804
2000 ; Santos-Silva et al.	4812
2000	4812
Santos-Silva et al.	4818
Santos-Silva	4818
et al.	4831
2007	4839
it	4855
individual therapies	4882
a panacea for spinal cord repair	4927
a panacea	4927
spinal cord repair	4941
a combinations of strategies	4971
a combinations	4971
strategies	4989
improvements in outcome	5014
improvements	5014
outcome	5030
spinal injury -LRB- Bunge , 2008 ; Lu and Tuszynski , 2008 -RRB-	5044
spinal injury	5044
Bunge , 2008 ; Lu and Tuszynski , 2008	5059
Bunge	5059
2008 ; Lu and Tuszynski	5066
2008	5066
Lu and Tuszynski	5072
2008	5090
The growth-promoting effect of OEC	5097
The growth-promoting effect	5097
OEC	5128
OECs	5177
Schwann cells and chondroitinase treatment	5187
Schwann cells	5187
chondroitinase treatment	5205
inhibition of the glial scar -LRB- Bretzner et al. , 2010 ; Fouad et al. , 2009b -RRB-	5242
inhibition	5242
the glial scar -LRB- Bretzner et al. , 2010 ; Fouad et al. , 2009b -RRB-	5256
the glial scar	5256
Bretzner	5272
et al. , 2010 ; Fouad et al. , 2009b	5281
et al.	5281
2010 ; Fouad et al.	5289
2010	5289
Fouad et al.	5295
Fouad	5295
et al.	5301
2009b	5309
It	5317
OEC	5352
degeneration of axotomized descending neurons	5370
degeneration	5370
axotomized descending neurons	5386
spinal cord injury -LRB- Xiao et al. , 2005 -RRB- and retinal ganglion cells	5422
spinal cord injury -LRB- Xiao et al. , 2005 -RRB-	5422
spinal cord injury	5422
Xiao	5442
et al. , 2005	5447
et al.	5447
2005	5455
retinal ganglion cells	5465
optic nerve lesion -LRB- Wu et al. , 2010 -RRB-	5494
optic nerve lesion	5494
Wu	5514
et al. , 2010	5517
et al.	5517
2010	5525
the growing number of reports	5546
the growing number	5546
reports	5568
the efficacy of OEC	5591
the efficacy	5591
OEC	5607
spinal cord repair -LRB- Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006 -RRB-	5622
spinal cord repair	5622
Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006	5642
Aoki	5642
et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006	5647
et al. , 2010	5647
et al.	5647
2010	5655
Barakat et al. , 2005	5661
Barakat	5661
et al. , 2005	5669
et al.	5669
2005	5677
Bretzner et al. , 2010	5683
Bretzner	5683
et al. , 2010	5692
et al.	5692
2010	5700
Collazos-Castro et al. , 2005	5706
Collazos-Castro	5706
et al. , 2005	5722
et al.	5722
2005	5730
Lu et al. , 2006	5736
Lu	5736
et al. , 2006	5739
et al.	5739
2006	5747
Steward et al. , 2006	5753
Steward	5753
et al. , 2006	5761
et al.	5761
2006	5769
It	5776
functional recovery after OEC transplantation	5802
functional recovery	5802
OEC transplantation	5828
collateral sprouting -LRB- Bradbury and McMahon , 2006 ; Toft et al. , 2007 -RRB- and migrating host Schwann cells -LRB- Boyd et al. , 2005 -RRB-	5870
collateral sprouting -LRB- Bradbury and McMahon , 2006 ; Toft et al. , 2007 -RRB-	5870
collateral sprouting	5870
collateral	5870
Bradbury and McMahon , 2006 ; Toft et al. , 2007	5892
Bradbury and McMahon	5892
2006 ; Toft et al.	5914
2006	5914
Toft et al.	5920
Toft	5920
et al.	5925
2007	5933
migrating host Schwann cells -LRB- Boyd et al. , 2005 -RRB-	5943
migrating host Schwann cells	5943
Boyd	5973
et al. , 2005	5978
et al.	5978
2005	5986
axonal regeneration across the lesion site	6007
axonal regeneration	6007
the lesion site	6034
The discrepancy in results	6051
The discrepancy	6051
results	6070
many factors including the source of tissue used to obtain the OEC , the age and the purity of transplanted cells and the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6101
many factors	6101
the source of tissue used to obtain the OEC , the age and the purity of transplanted cells and the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6124
the source	6124
tissue used to obtain the OEC , the age and the purity of transplanted cells and the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6138
tissue	6138
the OEC , the age and the purity of transplanted cells and the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6160
the OEC	6160
the age	6169
the purity of transplanted cells and the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6181
the purity	6181
transplanted cells and the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6195
transplanted cells	6195
the methodology used in culture preparation -LRB- Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 -RRB-	6218
the methodology used in culture preparation	6218
the methodology	6218
culture preparation	6242
Barnett and Riddell , 2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007	6263
Barnett and Riddell	6263
2007 ; Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li	6284
2007	6284
Kawaja et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li	6290
Kawaja	6290
et al. , 2009 ; Nieto-Sampedro , 2003 ; Raisman and Li	6297
et al. , 2009	6297
et al.	6297
2009	6305
Nieto-Sampedro , 2003	6311
Nieto-Sampedro	6311
2003	6327
Raisman and Li	6333
Raisman	6333
Li	6345
2007	6349
the type of spinal cord injury , the timing and the location of grafts within the injured spinal cord	6366
the type	6366
spinal cord injury , the timing and the location of grafts within the injured spinal cord	6378
spinal cord injury	6378
the timing	6398
the location of grafts within the injured spinal cord	6413
the location	6413
grafts within the injured spinal cord	6429
grafts	6429
the injured spinal cord	6443
the outcome of OEC transplantation	6488
the outcome	6488
OEC transplantation	6503
The present study	6524
OEC harvested from the adult rat olfactory bulbs and purified with a method of differential adhesion -LRB- Nash et al. , 2001 ; Sasaki et al. , 2004 -RRB- or with immunomagnetic beads -LRB- Gudino-Cabrera and Nieto-Sampedro , 1996 ; Lopez-Vales et al. , 2007 -RRB-	6563
OEC	6563
the adult rat olfactory bulbs	6582
a method of differential adhesion -LRB- Nash et al. , 2001 ; Sasaki et al. , 2004 -RRB-	6630
a method	6630
differential adhesion -LRB- Nash et al. , 2001 ; Sasaki et al. , 2004 -RRB-	6642
differential adhesion	6642
Nash	6665
et al. , 2001 ; Sasaki et al. , 2004	6670
et al.	6670
2001 ; Sasaki et al.	6678
2001	6678
Sasaki et al.	6684
Sasaki	6684
et al.	6691
2004	6699
immunomagnetic beads	6713
Gudino-Cabrera and Nieto-Sampedro , 1996 ; Lopez-Vales et al. , 2007	6735
Gudino-Cabrera and Nieto-Sampedro	6735
1996 ; Lopez-Vales et al.	6770
1996	6770
Lopez-Vales et al.	6776
Lopez-Vales	6776
et al.	6788
2007	6796
axonal regrowth	6818
the lesion site and support survival	6841
axotomized rubrospinal neurons	6895
cervical spinal cord hemisection in adult rats	6932
cervical spinal cord hemisection	6932
adult rats	6968
transplantation into the injured human spinal cord	6986
transplantation	6986
the injured human spinal cord	7007
large quantities of OEC	7050
large quantities	7050
OEC	7070
the time in culture	7105
the time	7105
culture	7117
we	7126
growth-promoting and neuroprotective effects of short-term and long-term cultured cells	7138
growth-promoting and neuroprotective effects	7138
short-term and long-term	7186
cells	7220
Materials and methods	7228
Materials	7228
methods	7242
Experimental animals The experiments were performed on adult -LRB- 10 -- 12 weeks , n = 96 -RRB- female Sprague -- Dawley rats	7250
Experimental animals	7250
The experiments	7271
adult -LRB- 10 -- 12 weeks , n = 96 -RRB- female Sprague -- Dawley rats	7305
adult -LRB- 10 -- 12 weeks , n = 96 -RRB- female Sprague	7305
adult	7305
10	7312
12 weeks , n = 96	7315
12 weeks	7315
n = 96	7325
n	7325
96	7327
female Sprague	7331
Dawley rats	7346
Taconic Europe A/S	7359
Denmark	7379
The animal care and experimental procedures	7389
The animal care	7389
experimental procedures	7409
accordance	7453
the European Communities Council Directive -LRB- 86 / 609/EEC -RRB-	7469
European Communities Council Directive -LRB- 86 / 609/EEC -RRB-	7473
European Communities Council Directive	7473
86	7513
609/EEC	7517
the Northern Swedish Committee for Ethics	7552
the Northern Swedish Committee	7552
Ethics	7587
Animal Experiments	7597
All surgical procedures	7617
general anesthesia using a mixture of ketamine -LRB- Ketalar ® , Parke-Davis ; 100 mg/kg i.v. -RRB- and xylazine -LRB- Rompun ® , Bayer ; 10 mg/kg i.v. -RRB-	7662
general anesthesia	7662
a mixture of ketamine -LRB- Ketalar ® , Parke-Davis ; 100 mg/kg i.v. -RRB- and xylazine -LRB- Rompun ® , Bayer ; 10 mg/kg i.v. -RRB-	7687
a mixture	7687
ketamine -LRB- Ketalar ® , Parke-Davis ; 100 mg/kg i.v. -RRB- and xylazine -LRB- Rompun ® , Bayer ; 10 mg/kg i.v. -RRB-	7700
ketamine	7700
Ketalar ® , Parke-Davis ; 100 mg/kg i.v.	7710
Ketalar ®	7710
Parke-Davis ; 100 mg/kg i.v.	7720
Parke-Davis	7720
100 mg/kg i.v.	7733
xylazine	7753
Rompun ® , Bayer ; 10 mg/kg i.v.	7763
Rompun ®	7763
Bayer ; 10 mg/kg i.v.	7772
Bayer	7772
10 mg/kg i.v.	7779
Culture of olfactory ensheathing cells Primary cultures of olfactory ensheathing cells -LRB- OEC -RRB-	7795
Culture of olfactory ensheathing cells Primary cultures of olfactory ensheathing cells	7795
Culture of olfactory ensheathing cells Primary cultures	7795
Culture of olfactory ensheathing cells	7795
Culture	7795
olfactory ensheathing cells	7806
olfactory ensheathing cells	7854
OEC	7883
technique -LRB- Novikova et al. , 2006 ; Pettersson et al. , 2010 ; Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	7929
technique	7929
Novikova et al. , 2006 ; Pettersson et al. , 2010 ; Ramon-Cueto and Nieto-Sampedro , 1994	7940
Novikova	7940
et al. , 2006 ; Pettersson et al. , 2010 ; Ramon-Cueto and Nieto-Sampedro , 1994	7949
et al. , 2006	7949
et al.	7949
2006	7957
Pettersson et al. , 2010	7963
Pettersson	7963
et al. , 2010	7974
et al.	7974
2010	7982
Ramon-Cueto and Nieto-Sampedro , 1994	7988
Ramon-Cueto and Nieto-Sampedro	7988
1994	8020
Adult female rats -LRB- n = 25 -RRB-	8027
Adult female rats	8027
n	8046
25	8048
killedwith an overdose of sodium pentobarbital -LRB- 240 mg / kg , Apoteks-bolaget , Sweden -RRB- and the olfactory bulbs -LRB- OB -RRB- were dissected into Hank 's balanced salt solution -LRB- HBSS , Invitrogen AB , Täby , Sweden -RRB- andcleaned fromblood clots andmeninges	8056
killedwith	8056
an overdose of sodium pentobarbital -LRB- 240 mg / kg , Apoteks-bolaget , Sweden -RRB- and the olfactory bulbs -LRB- OB -RRB-	8067
an overdose	8067
sodium pentobarbital -LRB- 240 mg / kg , Apoteks-bolaget , Sweden -RRB- and the olfactory bulbs -LRB- OB -RRB-	8082
sodium pentobarbital	8082
240 mg	8104
kg , Apoteks-bolaget , Sweden	8111
kg	8111
Apoteks-bolaget	8115
Sweden	8132
the olfactory bulbs	8144
OB	8165
Hank 's balanced salt solution -LRB- HBSS , Invitrogen AB , Täby , Sweden -RRB-	8189
Hank 's balanced salt solution	8189
Hank 's	8189
HBSS	8220
Invitrogen AB	8226
Täby , Sweden	8241
andcleaned fromblood clots andmeninges	8255
The olfactory nerve and glomerular layers	8295
The olfactory nerve	8295
glomerular layers	8319
the microscope	8358
small pieces	8383
Ca2	8415
+ and Mg2 + - free HBSS	8418
and Mg2	8420
- free HBSS	8428
free	8429
inHBSS	8454
the tissuewas	8462
0.1 % trypsin	8494
15 min at 37 °C	8511
15 min	8511
37 °C	8521
The enzymatic activity	8528
a mixture of DMEM and Ham 's F-12 medium -LRB- 1:1 ; Sigma-Aldrich Sweden AB , Stockholm , Sweden -RRB- supplemented with 2 mMglutamine , 10 U/mlpenicillin , 10 μg / ml streptomycin , 50 μg/ml gentamycin and 10 % fetal calf serum , FCS -LRB- `` D / F-10S medium '' from Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	8568
a mixture of DMEM and Ham 's F-12 medium -LRB- 1:1 ; Sigma-Aldrich Sweden AB , Stockholm , Sweden -RRB- supplemented with 2	8568
a mixture of DMEM and Ham 's F-12 medium -LRB- 1:1 ; Sigma-Aldrich Sweden AB , Stockholm , Sweden -RRB-	8568
a mixture of DMEM and Ham 's F-12 medium	8568
a mixture of DMEM and Ham 's	8568
a mixture	8568
DMEM and Ham	8581
1:1 ; Sigma-Aldrich Sweden AB	8609
1:1	8609
Sigma-Aldrich Sweden AB	8614
Stockholm , Sweden	8639
Stockholm	8639
Sweden	8650
2	8676
mMglutamine , 10 U/mlpenicillin ,	8678
mMglutamine	8678
10 U/mlpenicillin	8691
10 μg / ml streptomycin , 50 μg/ml gentamycin	8710
ml streptomycin , 50 μg/ml gentamycin	8717
ml streptomycin	8717
50 μg/ml gentamycin	8734
10 % fetal calf serum , FCS -LRB- `` D / F-10S medium '' from Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	8758
10 % fetal calf serum , FCS	8758
10 % fetal calf serum	8758
FCS	8780
D	8786
F-10S medium '' from Ramon-Cueto and Nieto-Sampedro , 1994	8789
F-10S medium ''	8789
Ramon-Cueto and Nieto-Sampedro	8808
1994	8840
The digestant	8847
800 rpm for 3 min , re-suspended and triturated	8880
800 rpm	8880
3 min	8892
5	8927
7 times	8929
a fire-polished , siliconized Pasteur pipette and 5	8945
a fire-polished	8945
Pasteur pipette and 5	8974
Pasteur pipette	8974
5	8994
7 times	8996
a 21 G needle	9012
the resulting primary culture	9033
a mixture of OEC , fibroblasts , endothelial cells and astrocytes	9073
a mixture	9073
OEC , fibroblasts , endothelial cells and astrocytes	9086
OEC	9086
fibroblasts	9091
endothelial cells	9104
astrocytes	9126
purification of OECwas	9138
purification	9138
OECwas	9154
a method of differential adhesion -LRB- a-OEC -RRB- -LRB- Nash et al. , 2001 -RRB- or immunomagneticbeads -LRB- b-OEC -RRB- -LRB- Gudino - Cabrera and Nieto-Sampedro , 1996 ; Lopez-Vales et al. , 2007 -RRB-	9176
a method	9176
differential adhesion -LRB- a-OEC -RRB- -LRB- Nash et al. , 2001 -RRB- or immunomagneticbeads -LRB- b-OEC -RRB- -LRB- Gudino - Cabrera and Nieto-Sampedro , 1996 ; Lopez-Vales et al. , 2007 -RRB-	9188
differential adhesion -LRB- a-OEC -RRB- -LRB- Nash et al. , 2001 -RRB-	9188
differential adhesion -LRB- a-OEC -RRB-	9188
differential adhesion	9188
a-OEC	9211
Nash	9219
et al. , 2001	9224
et al.	9224
2001	9232
immunomagneticbeads -LRB- b-OEC -RRB- -LRB- Gudino - Cabrera and Nieto-Sampedro , 1996 ; Lopez-Vales et al. , 2007 -RRB-	9240
immunomagneticbeads -LRB- b-OEC -RRB-	9240
immunomagneticbeads	9240
b-OEC	9261
Gudino	9269
Cabrera and Nieto-Sampedro , 1996 ; Lopez-Vales et al. , 2007	9277
Cabrera and Nieto-Sampedro	9277
1996 ; Lopez-Vales et al.	9305
1996	9305
Lopez-Vales et al.	9311
Lopez-Vales	9311
et al.	9323
2007	9331
The method of differential adhesion	9338
The method	9338
differential adhesion	9352
a very low adhesion rate of OEC	9386
a very low adhesion rate	9386
OEC	9414
the surface of uncoated culture flasks -LRB- Nash et al. , 2001 -RRB-	9421
the surface	9421
uncoated culture flasks -LRB- Nash et al. , 2001 -RRB-	9436
uncoated culture flasks	9436
Nash	9461
et al. , 2001	9466
et al.	9466
2001	9474
The cell suspension obtained from each pair of OB	9481
The cell suspension	9481
each pair of OB	9515
each pair	9515
OB	9528
D/F -10 S culture medium	9550
uncoated Lab-Tek ® one-chamber slides -LRB- Nalge Nunc International Corp -RRB-	9584
uncoated Lab-Tek ® one-chamber slides	9584
Nalge Nunc International Corp	9622
37 °C with 5 % CO2	9669
37 °C	9669
5 % CO2	9680
18 h	9694
the supernatant	9700
another uncoated Lab-Tek ® slide	9744
additional 36	9794
48 h	9808
The supernatants from three chamber slides -LRB- 6 olfactory bulbs from 3 rats -RRB-	9814
The supernatants from three chamber slides	9814
The supernatants	9814
three chamber slides	9836
6 olfactory bulbs from 3 rats	9858
6 olfactory bulbs	9858
3 rats	9881
25 cm2	9919
poly-L-lysine-coated culture flask	9926
D/F -10 S culture medium	9966
the procedure	9997
most of the non-OEC cells	10012
most	10012
the non-OEC cells	10020
the uncoated chamber slides -LRB- Nash et al. , 2001 -RRB-	10050
the uncoated chamber slides	10050
Nash	10079
et al. , 2001	10084
et al.	10084
2001	10092
The culture	10099
another 48 h	10129
OEC	10151
the poly-Llysine - coated surface of culture flask	10168
the poly-Llysine	10168
coated surface of culture flask	10186
coated surface	10186
culture flask	10204
the medium	10234
the cells	10245
Ca2	10272
+ and Mg2 + - free HBSS	10275
and Mg2	10277
- free HBSS	10285
free	10286
The resulting purity of a-OEC	10297
The resulting purity	10297
a-OEC	10321
93 -- 95 %	10331
93	10331
The immonumagnetic purification of OEC	10339
The immonumagnetic purification	10339
OEC	10374
1	10395
week-old primary cultures	10398
sheep anti-rabbit Dynabeads -LRB- M280 ; Dynal A.S. , Oslo , Norway -RRB- conjugated to low-affinity NGF receptor IgG -LRB- p75 ; Sigma-Aldrich Sweden AB , Stockholm , Sweden and Chemicon International , Ltd. , Malmö , Sweden -RRB- according to manufacturer 's recommendation	10430
sheep anti-rabbit Dynabeads	10430
M280 ; Dynal A.S. , Oslo , Norway	10459
M280	10459
Dynal A.S. , Oslo , Norway	10465
low-affinity NGF receptor IgG -LRB- p75 ; Sigma-Aldrich Sweden AB , Stockholm , Sweden and Chemicon International , Ltd. , Malmö , Sweden -RRB-	10505
low-affinity NGF receptor IgG	10505
p75 ; Sigma-Aldrich Sweden AB , Stockholm , Sweden and Chemicon International , Ltd. , Malmö , Sweden	10536
p75	10536
Sigma-Aldrich Sweden AB , Stockholm , Sweden and Chemicon International , Ltd. , Malmö , Sweden	10541
manufacturer 's recommendation	10646
manufacturer 's	10646
The Dynabeads	10677
p75 IgG for 24 h	10711
p75 IgG	10711
24 h	10723
4 °C -LRB- 2.5 μg of IgG for 107 of Dynabeads -RRB-	10731
4 °C	10731
2.5 μg of IgG for 107 of Dynabeads	10737
2.5 μg	10737
IgG for 107	10747
IgG	10747
107	10755
Dynabeads	10762
OEC suspension for 1 h at 4 °C -LRB- about 10 Dynabeads per target cell -RRB-	10787
OEC suspension	10787
1 h at 4 °C -LRB- about 10 Dynabeads per target cell -RRB-	10806
1 h	10806
4 °C -LRB- about 10 Dynabeads per target cell -RRB-	10813
4 °C	10813
10 Dynabeads per target cell	10825
10 Dynabeads	10825
target cell	10842
washing and re-suspension	10862
OEC	10889
25 cm2 poly-Llysine - coated culture flasks	10908
25 cm2 poly-Llysine	10908
coated culture flasks	10929
37 °C , 95 % humidity and 5 % CO2	10963
37 °C	10963
95 % humidity and 5 % CO2	10970
95 % humidity	10970
5 % CO2	10987
The resulting purity of b-OEC	10995
The resulting purity	10995
b-OEC	11019
80 %	11035
The cultures	11040
three different growthmediums : 1 -RRB- D/F -10 S -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB- , 2 -RRB- DMEM-10S with 2 μM forskolin and 20 μg/ml pituitary extract -LRB- Invitrogen AB , Täby , Sweden -RRB- as mitogens -LRB- Pastrana et al. , 2006 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Rubio et al. , 2008 -RRB- and 3 -RRB- D/F -10 S with 2 μM forskolin and recombinant human glial growth factor-2 -LRB- GGF2 , 40 ng/ml , Acorda Therapeutics , Inc. , Hawthorne , NY -RRB- as mitogens -LRB- Alexander et al. , 2002 ; Chuah et al. , 2000 ; Yan et al. , 2001 -RRB-	11073
three different growthmediums	11073
1 -RRB- D/F -10 S -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB- , 2 -RRB- DMEM-10S with 2 μM forskolin and 20 μg/ml pituitary extract -LRB- Invitrogen AB , Täby , Sweden -RRB- as mitogens -LRB- Pastrana et al. , 2006 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Rubio et al. , 2008 -RRB- and 3 -RRB- D/F -10 S with 2 μM forskolin and recombinant human glial growth factor-2 -LRB- GGF2 , 40 ng/ml , Acorda Therapeutics , Inc. , Hawthorne , NY -RRB- as mitogens -LRB- Alexander et al. , 2002 ; Chuah et al. , 2000 ; Yan et al. , 2001 -RRB-	11104
D/F	11107
-10 S -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB- , 2 -RRB- DMEM-10S with 2 μM forskolin and 20 μg/ml pituitary extract -LRB- Invitrogen AB , Täby , Sweden -RRB-	11110
-10 S -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB- , 2 -RRB- DMEM-10S with 2 μM forskolin	11110
-10 S	11110
Ramon-Cueto and Nieto-Sampedro , 1994	11116
Ramon-Cueto and Nieto-Sampedro	11116
1994	11148
2 -RRB- DMEM-10S with 2 μM forskolin	11155
DMEM-10S	11158
2 μM forskolin	11172
20 μg/ml pituitary extract -LRB- Invitrogen AB , Täby , Sweden -RRB-	11191
20 μg/ml	11191
pituitary extract -LRB- Invitrogen AB , Täby , Sweden -RRB-	11200
pituitary extract	11200
Invitrogen AB	11219
Täby	11234
Sweden	11240
mitogens -LRB- Pastrana et al. , 2006 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Rubio et al. , 2008 -RRB-	11251
mitogens	11251
Pastrana et al. , 2006 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Rubio et al. , 2008	11261
Pastrana	11261
et al. , 2006 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Rubio et al. , 2008	11270
et al. , 2006	11270
et al.	11270
2006	11278
Ramon-Cueto et al. , 1998	11284
Ramon-Cueto	11284
et al. , 1998	11296
et al.	11296
1998	11304
Ramon-Cueto et al. , 2000	11310
Ramon-Cueto	11310
et al. , 2000	11322
et al.	11322
2000	11330
Rubio et al. , 2008	11336
Rubio	11336
et al. , 2008	11342
et al.	11342
2008	11350
3 -RRB- D/F -10 S with 2 μM forskolin and recombinant human glial growth factor-2 -LRB- GGF2 , 40 ng/ml , Acorda Therapeutics , Inc. , Hawthorne , NY -RRB-	11360
3 -RRB- D/F -10 S with 2 μM forskolin	11360
D/F -10 S	11363
2 μM forskolin	11376
recombinant human glial growth factor-2 -LRB- GGF2 , 40 ng/ml , Acorda Therapeutics , Inc. , Hawthorne , NY -RRB-	11395
recombinant human glial growth factor-2	11395
GGF2 , 40 ng/ml , Acorda Therapeutics , Inc. , Hawthorne , NY	11436
GGF2	11436
40 ng/ml	11442
Acorda Therapeutics	11452
Inc.	11473
Hawthorne	11479
NY	11490
mitogens -LRB- Alexander et al. , 2002 ; Chuah et al. , 2000 ; Yan et al. , 2001 -RRB-	11497
mitogens	11497
Alexander et al. , 2002 ; Chuah et al. , 2000 ; Yan et al. , 2001	11507
Alexander	11507
et al. , 2002 ; Chuah et al. , 2000 ; Yan et al. , 2001	11517
et al. , 2002	11517
et al.	11517
2002	11525
Chuah et al. , 2000	11531
Chuah	11531
et al. , 2000	11537
et al.	11537
2000	11545
Yan et al. , 2001	11551
Yan	11551
et al. , 2001	11555
et al.	11555
2001	11563
The medium	11570
every second day	11593
experiments	11627
cells	11639
culture for 20 weeks	11664
culture	11664
20 weeks	11676
Population doublings and cumulative growth rate	11686
Population doublings	11686
cumulative growth rate	11711
a-OEC cultures	11753
the formula PD = log -LRB- number of cells harvested/number of cells seeded -RRB-	11781
the formula PD = log	11781
number of cells harvested/number of cells seeded	11801
number	11801
cells harvested/number of cells	11811
cells harvested/number	11811
cells	11837
log 2	11851
log	11851
2	11855
Rubio	11884
et al. , 2008	11890
et al.	11890
2008	11898
vivo experiments	11912
the time from OB dissection to OEC transplantation	11930
the time	11930
OB dissection to OEC transplantation	11944
OB dissection	11944
OEC transplantation	11961
3 weeks -LRB- short-termcultured cells , OEC ST -RRB- or 7 weeks -LRB- long-term cultured cells , OEC LT -RRB- and cells were expanded using growth medium D/F -10 S with forskolin and GGF2	11992
3 weeks -LRB- short-termcultured cells , OEC ST -RRB- or 7 weeks	11992
3 weeks -LRB- short-termcultured cells , OEC ST -RRB-	11992
short-termcultured cells , OEC ST	12001
short-termcultured cells , OEC	12001
short-termcultured cells	12001
OEC	12027
ST	12031
7 weeks	12038
long-term cultured cells , OEC LT	12047
long-term	12047
cells , OEC LT	12066
cells	12066
OEC LT	12073
cells were expanded using growth medium D/F -10 S with forskolin and GGF2	12085
cells	12085
growth medium D/F	12111
-10 S with forskolin and GGF2	12128
-10 S	12128
forskolin and GGF2	12138
The timing	12158
our preliminary findings	12182
OEC cultured for 7 and 20 weeks	12212
OEC	12212
7 and 20 weeks	12229
the same neuroprotective and growth-promoting effects	12248
spinal cord transplantation -LRB- unpublished observation -RRB-	12308
spinal cord transplantation	12308
unpublished observation	12337
The purity of transplanted OEC	12363
The purity	12363
transplanted OEC	12377
immunostaining for p75 receptors and S100 protein -LRB- see below -RRB-	12413
immunostaining	12413
p75 receptors and S100 protein -LRB- see below -RRB-	12432
p75 receptors and S100 protein	12432
p75 receptors	12432
S100 protein	12450
OEC	12476
Lab-Tek ® 8-chambers slides	12501
Lab-Tek	12501
8-chambers slides	12510
a density of 15,000 cells per well	12531
a density	12531
15,000 cells per well	12544
15,000 cells	12544
2 days	12570
4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH = 7.4 -RRB-	12597
4 % paraformaldehyde	12597
0.1 M phosphate buffer -LRB- pH = 7.4 -RRB-	12620
0.1 M phosphate buffer	12620
pH	12644
7.4	12647
room temperature for 20 min	12655
room temperature	12655
20 min	12676
OEC	12696
fluorescent	12718
Fast Blue -LRB- Sigma-Aldrich Sweden AB , Stockholm , Sweden -RRB- , cells were detached from culture flasks with Trypsin/EDTA and concentrated in the growth medium to 1 -- 3 × 106 cells/ml	12734
Fast Blue	12734
Sigma-Aldrich Sweden AB	12745
Stockholm	12770
Sweden	12781
cells were detached from culture flasks with Trypsin/EDTA and concentrated in the growth medium to 1 -- 3 × 106 cells/ml	12790
cells were detached from culture flasks with Trypsin/EDTA and concentrated in the growth medium to 1	12790
cells	12790
culture flasks	12815
Trypsin/EDTA	12835
the growth medium	12868
1	12889
3 × 106 cells/ml	12891
3 ×	12891
106 cells/ml	12893
Fast Bluewas	12907
cell suspension	12929
concentration 5 μl/ml for 15 min at 37 °C	12948
concentration 5 μl/ml	12948
15 min at 37 °C	12974
15 min	12974
37 °C	12984
labeling	12997
the cells	13007
25 cm2 poly-L-lysine-coated culture flasks	13047
25 cm2	13047
growth medium	13095
additional 72 h	13122
transplantation	13145
spinal cord -LRB- Pettersson et al. , 2010 -RRB-	13166
spinal cord	13166
Pettersson	13179
et al. , 2010	13190
et al.	13190
2010	13198
green fluorescent protein -LRB- GFP -RRB- in OEC -LRB- Fig. 1E -RRB-	13216
green fluorescent protein -LRB- GFP -RRB-	13216
green fluorescent protein	13216
GFP	13243
OEC -LRB- Fig. 1E -RRB-	13251
OEC	13251
Fig. 1E	13256
we	13266
retroviral expression system	13274
Retroviral packaging cell line PT67 -LRB- Clontech , Palo Alto , USA -RRB-	13304
Retroviral packaging cell line PT67	13304
Clontech	13341
Palo Alto	13351
USA	13362
high glucose DMEM -LRB- Invitrogen AB , Täby , Sweden -RRB- supplemented with penicillin , 100 U / ml , streptomycin 100 μg/ml -LRB- Invitrogen AB , Täby , Sweden -RRB- and 10 % FCS and transfected with a retroviral expression vector pLEGFPpuro	13385
high glucose DMEM	13385
Invitrogen AB	13404
Täby	13419
Sweden	13425
penicillin , 100 U / ml , streptomycin 100 μg/ml -LRB- Invitrogen AB , Täby , Sweden -RRB- and 10 % FCS	13451
penicillin	13451
100 U	13463
ml , streptomycin	13470
ml	13470
streptomycin	13474
100 μg/ml -LRB- Invitrogen AB , Täby , Sweden -RRB- and 10 % FCS	13487
100 μg/ml -LRB- Invitrogen AB , Täby , Sweden -RRB-	13487
Invitrogen AB	13498
Täby	13513
Sweden	13519
10 % FCS	13531
a retroviral expression vector pLEGFPpuro	13560
The GFP expression vector pLEGFPpuro	13603
substitution of the neomycin resistance gene in the retroviral vector pLEGFP-N1 -LRB- Clontech , Palo Alto , USA -RRB-	13654
substitution	13654
the neomycin resistance gene in the retroviral vector pLEGFP-N1 -LRB- Clontech , Palo Alto , USA -RRB-	13670
the neomycin resistance gene	13670
the retroviral vector pLEGFP-N1 -LRB- Clontech , Palo Alto , USA -RRB-	13702
the retroviral vector pLEGFP-N1	13702
Clontech	13735
Palo Alto	13745
USA	13756
the puromycin resistance gene	13764
pMSCVpuro -LRB- Clontech , Palo Alto , USA -RRB-	13799
pMSCVpuro	13799
Clontech	13810
Palo Alto	13820
USA	13831
The transfection of PT67 cells	13837
The transfection	13837
PT67 cells	13857
a lipofection method with Lipofectamin 2000 -LRB- Invitrogen , Carlsbad , USA -RRB-	13880
a lipofection method	13880
Lipofectamin 2000	13906
Invitrogen	13925
Carlsbad	13937
USA	13947
the protocol provided by the manufacturer	13965
the protocol	13965
the manufacturer	13990
cells were selected with puromycin and maintained -LRB- Clontech , Palo Alto , USA -RRB-	14033
cells were selected with puromycin and maintained	14033
cells	14033
puromycin	14058
Clontech	14084
Palo Alto	14094
USA	14105
virus production	14115
the packaging cells	14133
confluence about 60 %	14168
confluence	14168
60 %	14185
37 °C	14213
a 32 °C incubator	14240
95 % humidity and 5 % CO2	14263
95 % humidity	14263
5 % CO2	14280
72 h	14294
virus containing medium	14300
virus	14300
medium	14317
0.45 μm low-protein binding filter -LRB- Pall Corporation , Cornwall , UK -RRB-	14359
0.45 μm low-protein binding filter	14359
0.45 μm	14359
low-protein binding filter	14367
Pall Corporation , Cornwall , UK	14395
Pall Corporation , Cornwall	14395
UK	14423
transduction	14432
OEC	14446
a density of 5 × 103 cells per cm2	14465
a density	14465
5 × 103 cells per cm2	14478
5 × 103 cells	14478
cm2	14494
2 days later	14502
their growth medium	14515
the viral medium containing 8 μl/ml polybrene -LRB- Sigma-Aldrich , Milwaukee , USA -RRB-	14553
the viral medium	14553
8 μl/ml polybrene -LRB- Sigma-Aldrich , Milwaukee , USA -RRB-	14581
8 μl/ml polybrene	14581
Sigma-Aldrich	14600
Milwaukee	14615
USA	14626
The cells	14632
32 °C for 24 h	14655
32 °C	14655
24 h	14665
transduction	14677
the viral medium	14691
a fresh OEC growth medium	14723
Transduction efficacy	14750
about 40 %	14776
incubation at 37 °C for 48 h	14797
incubation	14797
37 °C for 48 h	14811
37 °C	14811
48 h	14821
the GFP-positive cells	14827
non-transduced cells	14870
fluorescence activated cell sorter technique -LRB- FACS DiVa , BD Biosciences , San Jose , USA -RRB-	14894
fluorescence	14894
cell sorter technique -LRB- FACS DiVa , BD Biosciences , San Jose , USA -RRB-	14917
cell sorter technique	14917
FACS DiVa , BD Biosciences , San Jose , USA	14940
FACS DiVa	14940
BD Biosciences	14951
San Jose	14967
USA	14977
Spinal cord injury and transplantation	14983
Spinal cord injury	14983
transplantation	15006
cervical laminectomy , the lateral funiculus and adjacent gray matter of the C4 spinal cord segment	15028
cervical laminectomy	15028
the lateral funiculus	15050
adjacent gray matter of the C4 spinal cord segment	15076
adjacent gray matter	15076
the C4 spinal cord segment	15100
the left side	15146
The rats	15161
experimental groups receiving different treatments	15197
experimental groups	15197
different treatments	15227
i	15250
spinal cord injury -LRB- SCI -RRB- without treatment -LRB- SCI , n = 17 -RRB- , -LRB- ii -RRB- SCI followed by transplantation of short-term cultured a-OEC -LRB- a-OEC ST , n = 14 -RRB- , -LRB- iii -RRB- SCI followed by transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15253
spinal cord injury -LRB- SCI -RRB-	15253
spinal cord injury	15253
SCI	15273
treatment -LRB- SCI , n = 17 -RRB- , -LRB- ii -RRB- SCI followed by transplantation of short-term cultured a-OEC -LRB- a-OEC ST , n = 14 -RRB- , -LRB- iii -RRB- SCI followed by transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15286
treatment -LRB- SCI , n = 17 -RRB-	15286
treatment	15286
SCI , n = 17	15297
SCI	15297
n = 17	15302
n	15302
17	15304
-LRB- ii -RRB- SCI followed by transplantation of short-term cultured a-OEC -LRB- a-OEC ST , n = 14 -RRB- , -LRB- iii -RRB- SCI followed by transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15309
SCI	15314
transplantation of short-term cultured a-OEC -LRB- a-OEC ST , n = 14 -RRB- , -LRB- iii -RRB- SCI followed by transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15330
transplantation	15330
short-term cultured a-OEC -LRB- a-OEC ST , n = 14 -RRB- , -LRB- iii -RRB- SCI followed by transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15349
short-term cultured a-OEC -LRB- a-OEC ST , n = 14 -RRB-	15349
short-term cultured a-OEC	15349
a-OEC ST , n = 14	15376
a-OEC ST	15376
n = 14	15386
n	15386
14	15388
-LRB- iii -RRB- SCI followed by transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15393
SCI	15399
transplantation of long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15415
transplantation	15415
long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB- and -LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15434
long-term cultured a-OEC -LRB- a-OEC LT , n = 17 -RRB-	15434
long-term cultured a-OEC	15434
a-OEC LT , n = 17	15460
a-OEC LT	15460
n = 17	15470
n	15470
17	15472
-LRB- iv -RRB- SCI followed by transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15480
SCI	15485
transplantation of short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15501
transplantation	15501
short-term cultured b-OEC -LRB- b-OEC ST , n = 13 -RRB-	15520
short-term cultured b-OEC	15520
b-OEC ST , n = 13	15547
b-OEC ST	15547
n = 13	15557
n	15557
13	15559
Transplantation of long-term cultured b-OEC was not performed since our results in vitro	15564
Transplantation	15564
long-term cultured b-OEC was not performed since our results in vitro	15583
long-term	15583
b-OEC	15602
our results	15632
Results , Olfactory ensheathing cell culture	15658
Results	15658
Olfactory ensheathing cell culture	15667
it	15721
80 % purity of b-OEC	15753
80 % purity	15753
b-OEC	15767
more than 2 -- 3 weeks due to contamination	15777
more than 2	15777
3 weeks	15789
contamination	15804
non-OEC cells	15823
Five rats at 1 week after Fast Blue application to the lumbar spinal cord and 5 rats at 1 week after anterograde labeling of rubrospinal axons with biotinylated dextran amine -LRB- `` control '' in histograms -RRB-	15838
Five rats	15838
1 week	15851
Fast Blue application	15864
the lumbar spinal cord and 5 rats	15889
the lumbar spinal cord	15889
5 rats	15916
1 week after anterograde labeling of rubrospinal axons	15926
1 week	15926
anterograde labeling of rubrospinal axons	15939
anterograde labeling	15939
rubrospinal axons	15963
dextran amine	15999
`` control '' in histograms	16014
`` control ''	16014
histograms	16027
baseline controls	16049
transplantation , the cells cultured in D/F -10 Swith	16072
transplantation	16072
the cells cultured in D/F -10 Swith	16089
the cells	16089
D/F -10 Swith	16111
2 μMforskolin and recombinant human GGF-2	16123
2 μMforskolin	16123
recombinant human GGF-2	16141
Trypsin/EDTA	16184
105 cells/μl in the growth mediumwithout serum	16225
105 cells/μl	16225
the growth mediumwithout serum	16241
transfer into a siliconized glass micropipette -LRB- outer diameter 100 μm -RRB- attached to a 5 μl Hamiltone syringe	16279
transfer	16279
a siliconized glass micropipette -LRB- outer diameter 100 μm -RRB- attached to a 5 μl Hamiltone syringe	16293
a siliconized glass micropipette	16293
outer diameter 100 μm	16327
outer diameter	16327
100 μm	16342
a 5 μl Hamiltone syringe	16362
1.5 -- 1.6 μl of the cell suspension -LRB- 150,000 -- 160,000 cells -RRB- was slowly -LRB- 10 min -RRB-	16388
1.5 -- 1.6	16388
μl of the cell suspension -LRB- 150,000 -- 160,000 cells -RRB-	16396
μl	16396
the cell suspension -LRB- 150,000 -- 160,000 cells -RRB-	16402
the cell suspension	16402
150,000 -- 160,000 cells	16423
150,000	16423
160,000 cells	16431
10 min	16458
the lateral funiculus -LRB- depths 1.0 mm -RRB-	16489
the lateral funiculus	16489
depths 1.0 mm	16512
depths	16512
1.0 mm	16519
approximately 1 mm rostral and 1 mm caudal to the lesion site	16530
approximately 1 mm rostral	16530
1 mm caudal to the lesion site	16561
1 mm caudal	16561
the lesion site	16576
Stoelting 's Lab Standard Stereotaxic Instrument -LRB- Stoelting Co. , USA -RRB-	16598
Stoelting 's Lab Standard Stereotaxic Instrument	16598
Stoelting 's	16598
Stoelting Co.	16647
USA	16662
The micropipette	16668
place for additional 2 -- 3 min	16697
place for additional 2	16697
place	16697
additional 2	16707
3 min	16720
Dura mater	16726
stretched parafilm	16754
Spongostan ® , muscles and skin	16777
Spongostan ®	16777
muscles	16790
skin	16802
layers	16822
the rats	16834
analgesic Finadyne -LRB- Schering-Plough , Denmark ; 2.5 mg/kg , i.m. -RRB- , saline -LRB- 2 ml s.c. -RRB- and benzylpenicillin -LRB- Boehringer Ingelheim ; 60 mg i.m. -RRB-	16854
analgesic Finadyne -LRB- Schering-Plough , Denmark ; 2.5 mg/kg , i.m. -RRB- , saline -LRB- 2 ml s.c. -RRB- and benzylpenicillin	16854
analgesic Finadyne -LRB- Schering-Plough , Denmark ; 2.5 mg/kg , i.m. -RRB-	16854
analgesic Finadyne	16854
Schering-Plough , Denmark	16874
2.5 mg/kg , i.m.	16900
2.5 mg/kg	16900
i.m.	16911
saline -LRB- 2 ml s.c. -RRB-	16918
saline	16918
2 ml s.c.	16926
benzylpenicillin	16941
Boehringer Ingelheim ; 60 mg i.m.	16959
Boehringer Ingelheim	16959
60 mg i.m.	16981
Retrograde labeling of rubrospinal neurons	16994
Retrograde labeling	16994
rubrospinal neurons	17017
the experiments	17040
neuronal survival , rubrospinal neurons	17069
neuronal survival	17069
rubrospinal neurons	17088
retrograde tracer	17126
1 week	17144
SCI -LRB- Novikova et al. , 2002 -RRB-	17158
SCI	17158
Novikova	17163
et al. , 2002	17172
et al.	17172
2002	17180
a laminectomy	17197
the L1 spinal cord segment	17212
the L1	17212
spinal cord segment	17219
the dorsal portion of the left lateral funiculus including the rubrospinal tract	17255
the dorsal portion	17255
the left lateral funiculus including the rubrospinal tract	17277
the left lateral funiculus	17277
the rubrospinal tract	17314
a fine scissors	17356
an operating microscope	17378
A small pellet prepared from 1 to 2 μl of a 2 % aqueous solution of the non-toxic fluorescent tracer Fast Blue -LRB- Sigma-Aldrich Sweden AB -RRB-	17403
A small pellet	17403
1 to 2 μl of a 2 % aqueous solution of the non-toxic fluorescent tracer Fast Blue	17432
1 to 2 μl	17432
a 2 % aqueous solution of the non-toxic fluorescent tracer Fast Blue	17445
a 2 % aqueous solution	17445
the non-toxic fluorescent tracer Fast Blue	17470
the non-toxic fluorescent tracer	17470
Fast Blue	17503
Sigma-Aldrich Sweden AB	17514
the lesion cavity	17555
a thin sheet of parafilm and a small piece of Spongostan ®	17590
a thin sheet of parafilm	17590
a thin sheet	17590
parafilm	17606
a small piece of Spongostan ®	17619
a small piece	17619
Spongostan ®	17636
Anterograde tracing of rubrospinal axons Anterograde labeling of rubrospinal axons	17649
Anterograde	17649
rubrospinal axons	17672
Anterograde labeling of rubrospinal axons	17690
Anterograde labeling	17690
rubrospinal axons	17714
us previously -LRB- Novikova et al. , 2002 -RRB-	17762
us previously	17762
us	17762
Novikova	17777
et al. , 2002	17786
et al.	17786
2002	17794
brief	17804
12 weeks after spinal cord injury	17814
12 weeks	17814
spinal cord injury	17829
the rats	17849
a stereotaxic frame	17874
a 2 mm hole	17898
the skull	17925
access	17944
the red nucleus	17954
A glass micropipette -LRB- outer tip diameter 40 -- 50 μm -RRB- filled with a 10 % solution of biotinylated dextran amine in saline -LRB- BDA ; 10 000 MW , lysine fixable , Molecular Probes -RRB-	17971
A glass micropipette -LRB- outer tip diameter 40 -- 50 μm -RRB-	17971
A glass micropipette	17971
outer tip diameter	17993
40 -- 50 μm	18012
40	18012
50 μm	18016
a 10 % solution of biotinylated dextran amine in saline -LRB- BDA ; 10 000 MW , lysine fixable , Molecular Probes -RRB-	18035
a 10 % solution	18035
dextran amine in saline	18066
dextran amine	18066
saline	18083
BDA ; 10 000 MW	18091
BDA	18091
10 000 MW	18096
10 000	18096
MW	18103
lysine fixable , Molecular Probes	18107
lysine fixable	18107
Molecular Probes	18123
stereotaxic insertions	18154
the magnocellular and parvicellular regions of the red nucleus -LRB- 6.6 and 6.1 mm caudal to the bregma , 0.7 mm lateral to the midline , and 7.2 mm ventral to the bregma -RRB-	18182
the magnocellular and parvicellular regions	18182
the red nucleus -LRB- 6.6 and 6.1 mm caudal to the bregma , 0.7 mm lateral to the midline , and 7.2 mm ventral to the bregma -RRB-	18229
the red nucleus	18229
6.6 and 6.1 mm caudal to the bregma , 0.7 mm lateral to the midline , and 7.2 mm ventral to the bregma	18246
6.6 and 6.1 mm caudal to the bregma	18246
6.6 and 6.1 mm caudal	18246
the bregma	18271
0.7 mm lateral to the midline	18283
0.7 mm lateral	18283
the midline	18301
7.2 mm ventral to the bregma	18318
7.2 mm	18318
the bregma	18336
Stoelting 's Lab Standard Stereotaxic Instrument -LRB- Stoelting Co. , USA -RRB-	18354
Stoelting 's Lab Standard Stereotaxic Instrument	18354
Stoelting 's	18354
Stoelting Co.	18403
USA	18418
BDA	18424
anodal current pulses of 10 μA -LRB- 7 s on/7 s off -RRB-	18470
anodal current pulses	18470
10 μA -LRB- 7 s on/7 s off -RRB-	18495
10 μA	18495
7 s on/7 s off	18502
7 s	18502
on/7 s off	18506
on/7 s	18506
the microelectrode for 10 min	18526
the microelectrode	18526
10 min	18549
The microelectrode	18557
place for additional 2 -- 3 min	18593
place for additional 2	18593
place	18593
additional 2	18603
3 min	18616
Tissue processing	18623
3	18644
8 and 13 weeks the animals	18647
8 and 13 weeks	18647
the animals	18662
an intraperitoneal overdose of sodium pentobarbital	18704
an intraperitoneal overdose	18704
sodium pentobarbital	18735
Tyrode 's solution followed by 4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	18789
Tyrode 's solution	18789
Tyrode 's	18789
4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	18819
4 % paraformaldehyde	18819
0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	18842
0.1 M phosphate buffer	18842
pH 7.4	18866
the experiments	18878
anterograde BDA-labeling	18900
the fixation	18926
a mixture of 4 % paraformaldehyde and 0.5 % glutaraldehyde	18952
a mixture	18952
4 % paraformaldehyde and 0.5 % glutaraldehyde	18965
4 % paraformaldehyde	18965
0.5 % glutaraldehyde	18989
0.1 Mphosphate buffer -LRB- pH = 7.4 -RRB-	19012
0.1 Mphosphate buffer	19012
pH	19035
7.4	19038
Spinal cord segments C3 -- C5 and the brain stem were then removed and transferred into the same fixative .	19044
Spinal cord segments C3	19044
C5 and the brain stem	19068
C5	19068
the brain stem	19075
the same fixative	19129
immunohistochemistry	19152
spinal cord segments C3 -- C5	19174
spinal cord segments C3	19174
C5	19198
1 -- 2 h , cryoprotected in 10 % and 20 % sucrose for 2 --	19221
1	19221
2 h , cryoprotected in 10 % and 20 % sucrose for 2	19223
2 h , cryoprotected in 10 %	19223
2 h	19223
10 %	19245
20 % sucrose for 2	19253
20 % sucrose	19253
2	19269
3 days	19271
liquid isopentane	19292
Serial longitudinal 16-μm-thick sections	19311
a cryomicrotome -LRB- Leica Instruments , Germany -RRB- , thaw-mounted in pairs	19364
a cryomicrotome	19364
Leica Instruments	19381
Germany	19400
pairs	19426
SuperFrost ® Plus slides	19437
overnight	19467
room temperature	19480
− 85 °C	19511
processing	19525
fluorescence microscopy and cell counts	19541
50-μm-thick serial transverse sections from the midbrain	19582
50-μm-thick serial transverse sections	19582
the midbrain	19626
a vibratome -LRB- Leica Instruments , Germany -RRB-	19651
a vibratome	19651
Leica Instruments	19664
Germany	19683
gelatin-coated glass slides	19704
air	19733
xylene	19764
DPX -LRB- Kebo Lab AB , Sweden -RRB-	19791
DPX	19791
Kebo Lab AB	19796
Sweden	19809
demonstration of anterogradely BDA-labeled rubrospinal axons and arborizations	19822
demonstration	19822
anterogradely BDA-labeled rubrospinal axons and arborizations	19839
anterogradely BDA-labeled rubrospinal axons	19839
arborizations	19887
serial 50-μm-thick transverse sections -LRB- C3 spinal cord segments -RRB- and longitudinal sections -LRB- C4 -- C5 spinal cord segments -RRB-	19902
serial 50-μm-thick transverse sections -LRB- C3 spinal cord segments -RRB-	19902
serial 50-μm-thick transverse sections	19902
C3 spinal cord segments	19942
C3	19942
spinal cord segments	19945
longitudinal sections -LRB- C4 -- C5 spinal cord segments -RRB-	19971
longitudinal sections	19971
C4	19994
C5 spinal cord segments	19997
C5	19997
spinal cord segments	20000
a cryomicrotome or vibratome	20034
a modified ABC method -LRB- Novikova et al. , 2002 -RRB-	20090
a modified ABC method	20090
Novikova	20113
et al. , 2002	20122
et al.	20122
2002	20130
free-floating sections	20146
PBS	20184
6 h at room temperature	20203
6 h	20203
room temperature	20210
avidin -- biotin -- peroxidase complex -LRB- 1:1:100 ; Vector Laboratories , Burlingame , CA -RRB- in PBS containing 0.3 % Triton X-100 and 1 % bovine serum albumin	20232
avidin	20232
biotin -- peroxidase complex -LRB- 1:1:100 ; Vector Laboratories , Burlingame , CA -RRB- in PBS containing 0.3 % Triton X-100 and 1 % bovine serum albumin	20239
biotin	20239
peroxidase complex -LRB- 1:1:100 ; Vector Laboratories , Burlingame , CA -RRB- in PBS containing 0.3 % Triton X-100 and 1 % bovine serum albumin	20246
peroxidase complex -LRB- 1:1:100 ; Vector Laboratories , Burlingame , CA -RRB-	20246
peroxidase complex	20246
1:1:100 ; Vector Laboratories	20266
1:1:100	20266
Vector Laboratories	20275
Burlingame , CA	20296
Burlingame	20296
CA	20308
PBS containing 0.3 % Triton X-100 and 1 % bovine serum albumin	20315
PBS	20315
0.3 % Triton X-100 and 1 % bovine serum albumin	20330
0.3 % Triton X-100	20330
1 % bovine serum albumin	20352
1 %	20352
a solution containing 0.05 % of 3,3 ′ - diaminobenzidine tetrahydrochloride -LRB- DAB , Sigma -RRB- , 0.06 % NiCl2 and 0.003 % H2O2	20390
a solution	20390
0.05 % of 3,3 ′ - diaminobenzidine tetrahydrochloride -LRB- DAB , Sigma -RRB- , 0.06 % NiCl2 and 0.003 % H2O2	20412
0.05 % of 3,3 ′ - diaminobenzidine tetrahydrochloride -LRB- DAB , Sigma -RRB-	20412
0.05 % of 3,3 ′	20412
0.05 %	20412
3,3	20421
diaminobenzidine tetrahydrochloride -LRB- DAB , Sigma -RRB-	20426
diaminobenzidine tetrahydrochloride	20426
DAB	20463
Sigma	20468
0.06 % NiCl2	20476
0.06 %	20476
NiCl2	20482
0.003 % H2O2	20492
0.003 %	20492
H2O2	20499
glass slides	20516
cresyl violet	20550
DPX	20584
Immunohistochemistry Immunostaining	20589
longitudinal 16-μm-thick spinal cord sections and cells cultured on Lab-Tek ® slides	20642
longitudinal 16-μm-thick spinal cord sections and cells	20642
Lab-Tek ® slides	20710
normal serum	20747
the following primary antibodies	20761
mouse anti-low-affinity NGF p75 receptor -LRB- 1:200 ; Chemicon International , Ltd. -RRB- , mouse anti-Thy 1.1 -LRB- 1:1000 ; MAB1406 Chemicon -RRB- , rabbit anti-S-100 protein -LRB- 1:1000 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-GFAP -LRB- 1:500 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-serotonin , -LRB- 1:1000 ; Sigma-Aldrich Sweden AB -RRB- , rabbit anti-CGRP -LRB- 1:1000 ; Chemicon International , Ltd. -RRB- , rabbit anti-GFP -LRB- 1:500 ; Molecular Probes , Invitrogen -RRB- , and a cocktail of monoclonal antibodies reacting with 68 , 160 and 200 kDa neurofilament proteins -LRB- pan-NF ; 1:200 ; Zymed ; Labora AB , Sollentuna , Sweden -RRB-	20805
mouse anti-low-affinity NGF p75 receptor -LRB- 1:200 ; Chemicon International , Ltd. -RRB- , mouse anti-Thy 1.1 -LRB- 1:1000 ; MAB1406 Chemicon -RRB- , rabbit anti-S-100 protein -LRB- 1:1000 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-GFAP -LRB- 1:500 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-serotonin , -LRB- 1:1000 ; Sigma-Aldrich Sweden AB -RRB- , rabbit anti-CGRP -LRB- 1:1000 ; Chemicon International , Ltd. -RRB- , rabbit anti-GFP -LRB- 1:500 ; Molecular Probes , Invitrogen -RRB- , and a cocktail of monoclonal antibodies	20805
mouse	20805
anti-low-affinity NGF p75 receptor -LRB- 1:200 ; Chemicon International , Ltd. -RRB- , mouse anti-Thy 1.1 -LRB- 1:1000 ; MAB1406 Chemicon -RRB- , rabbit anti-S-100 protein -LRB- 1:1000 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-GFAP -LRB- 1:500 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-serotonin , -LRB- 1:1000 ; Sigma-Aldrich Sweden AB -RRB- , rabbit anti-CGRP -LRB- 1:1000 ; Chemicon International , Ltd. -RRB- , rabbit anti-GFP -LRB- 1:500 ; Molecular Probes , Invitrogen -RRB- , and a cocktail of monoclonal antibodies	20811
anti-low-affinity NGF p75 receptor -LRB- 1:200 ; Chemicon International , Ltd. -RRB-	20811
anti-low-affinity NGF p75 receptor	20811
1:200	20847
Chemicon International , Ltd.	20854
Chemicon International	20854
Ltd.	20878
mouse anti-Thy 1.1 -LRB- 1:1000 ; MAB1406 Chemicon -RRB-	20885
mouse anti-Thy 1.1	20885
mouse	20885
1.1	20900
1:1000 ; MAB1406 Chemicon	20905
1:1000	20905
MAB1406 Chemicon	20913
rabbit anti-S-100 protein -LRB- 1:1000 ; Dakopatts AB , Älvsjö , Sweden -RRB-	20932
rabbit anti-S-100 protein	20932
1:1000 ; Dakopatts AB , Älvsjö , Sweden	20959
1:1000	20959
Dakopatts AB , Älvsjö , Sweden	20967
rabbit anti-GFAP -LRB- 1:500 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-serotonin , -LRB- 1:1000 ; Sigma-Aldrich Sweden AB -RRB-	20998
rabbit anti-GFAP -LRB- 1:500 ; Dakopatts AB , Älvsjö , Sweden -RRB- , rabbit anti-serotonin ,	20998
rabbit anti-GFAP -LRB- 1:500 ; Dakopatts AB , Älvsjö , Sweden -RRB-	20998
rabbit anti-GFAP	20998
1:500 ; Dakopatts AB , Älvsjö , Sweden	21016
1:500	21016
Dakopatts AB , Älvsjö , Sweden	21023
rabbit anti-serotonin	21054
1:1000 ; Sigma-Aldrich Sweden AB	21078
1:1000	21078
Sigma-Aldrich Sweden AB	21086
rabbit anti-CGRP -LRB- 1:1000 ; Chemicon International , Ltd. -RRB-	21112
rabbit anti-CGRP	21112
1:1000	21130
Chemicon International , Ltd.	21138
Chemicon International	21138
Ltd.	21162
rabbit anti-GFP -LRB- 1:500 ; Molecular Probes , Invitrogen -RRB-	21169
rabbit anti-GFP	21169
1:500	21186
Molecular Probes , Invitrogen	21193
Molecular Probes	21193
Invitrogen	21211
a cocktail of monoclonal antibodies	21228
a cocktail	21228
monoclonal antibodies	21242
68 , 160 and 200	21278
kDa neurofilament proteins -LRB- pan-NF ; 1:200 ; Zymed ; Labora AB , Sollentuna , Sweden	21294
kDa neurofilament proteins -LRB- pan-NF ; 1:200 ; Zymed	21294
kDa neurofilament proteins -LRB- pan-NF ; 1:200 ;	21294
kDa neurofilament proteins	21294
pan-NF ; 1:200	21322
pan-NF	21322
1:200	21330
Labora AB , Sollentuna , Sweden	21344
Labora AB	21344
Sollentuna , Sweden	21355
All primary antibodies	21376
2 h at room temperature	21416
2 h	21416
room temperature	21423
PBS , secondary goat anti-mouse and goat anti-rabbit antibodies	21458
PBS	21458
secondary goat anti-mouse	21463
goat anti-rabbit antibodies	21493
Alexa Fluor ® 488 and Alexa Fluor ® 568	21521
Alexa Fluor ® 488	21521
Alexa Fluor	21521
488	21534
Alexa Fluor ® 568	21542
Alexa Fluor	21542
568	21555
1:300 ; Molecular Probes , Invitrogen	21560
1:300	21560
Molecular Probes , Invitrogen	21567
Molecular Probes	21567
Invitrogen	21585
1 h	21614
room temperature in the dark	21621
room temperature	21621
the dark	21641
The slides	21651
Vectashield ® mounting medium -LRB- Vector Laboratories -RRB-	21685
Vectashield ® mounting medium	21685
Vector Laboratories	21715
The staining specificity	21737
omission of primary antibodies	21776
omission	21776
primary antibodies	21788
Counts of Fast Blue-labeled rubrospinal neurons The nuclear profiles of the retrogradely labeled neurons	21808
Counts	21808
Fast Blue-labeled rubrospinal neurons The nuclear profiles of the retrogradely labeled neurons	21818
Fast Blue-labeled rubrospinal neurons	21818
The nuclear profiles of the retrogradely labeled neurons	21856
The nuclear profiles	21856
the retrogradely labeled neurons	21880
the retrogradely	21880
neurons	21905
all sections	21929
the red nucleus at 250 × magnification	21950
the red nucleus	21950
250 × magnification	21969
The total number of profiles	21989
The total number	21989
profiles	22009
split nuclei	22040
the nuclear diameters	22060
comparison with the section thickness used -LRB- Novikova et al. , 2000 , 2002 -RRB-	22096
comparison	22096
the section thickness used	22112
the section thickness	22112
Novikova	22140
et al. , 2000 , 2002	22149
et al.	22149
2000	22157
2002	22163
We	22170
the accuracy of this technique in estimation of retrograde cell death	22207
the accuracy	22207
this technique in estimation of retrograde cell death	22223
this technique	22223
estimation of retrograde cell death	22241
estimation	22241
retrograde cell death	22255
that obtained with physical disector method -LRB- Ma et al. , 2001 -RRB- and counts of neurons reconstructed from serial sections -LRB- Novikov et al. , 1997 -RRB-	22291
that	22291
physical disector method -LRB- Ma et al. , 2001 -RRB- and counts of neurons reconstructed from serial sections -LRB- Novikov et al. , 1997 -RRB-	22310
physical disector method -LRB- Ma et al. , 2001 -RRB-	22310
physical disector method	22310
Ma	22336
et al. , 2001	22339
et al.	22339
2001	22347
counts of neurons reconstructed from serial sections -LRB- Novikov et al. , 1997 -RRB-	22357
counts	22357
neurons reconstructed from serial sections -LRB- Novikov et al. , 1997 -RRB-	22367
neurons	22367
serial sections -LRB- Novikov et al. , 1997 -RRB-	22394
serial sections	22394
Novikov	22411
et al. , 1997	22419
et al.	22419
1997	22427
Counts of rubrospinal axons and arborizations Rubrospinal sprouting	22434
Counts of rubrospinal axons and arborizations Rubrospinal	22434
Counts of rubrospinal axons and arborizations	22434
Counts	22434
rubrospinal axons and arborizations	22444
20 randomly selected transverse sections	22517
the C2 spinal cord segment of normal rats	22563
the C2 spinal cord segment	22563
normal rats	22593
13 weeks after SCI and cell transplantation as described previously -LRB- Novikova et al. , 2002 -RRB-	22612
13 weeks after SCI	22612
13 weeks	22612
SCI	22627
cell transplantation as described previously -LRB- Novikova et al. , 2002 -RRB-	22635
cell transplantation	22635
Novikova	22681
et al. , 2002	22690
et al.	22690
2002	22698
Rubrospinal arborizations in lamina V of the C2 spinal segment	22705
Rubrospinal arborizations	22705
lamina V of the C2 spinal segment	22734
lamina V	22734
the C2 spinal segment	22746
four nonoverlapping areas at 2000 final magnification with a Nikon DXM1200 digital camera	22785
four nonoverlapping areas	22785
2000 final magnification with a Nikon DXM1200 digital camera	22814
2000 final magnification	22814
a Nikon DXM1200 digital camera	22844
Matrox Inspector 3.1 software -LRB- Matrox Electronic Systems Ltd. , Quebec , Canada -RRB-	22893
Matrox Inspector 3.1 software	22893
Matrox Inspector	22893
3.1 software	22910
Matrox Electronic Systems Ltd. , Quebec , Canada	22924
Matrox Electronic Systems Ltd.	22924
Quebec , Canada	22956
The final image size	22973
1280 × 1024 pixels	22998
1280	22998
1024 pixels	23003
the area of 54.18 × 43.35 μm	23035
the area	23035
54.18 × 43.35 μm	23047
54.18 ×	23047
43.35 μm	23054
The number of labeled profiles and the relative tissue area occupied by labeled profiles were quantified for each image at a constant discrimination level and an average value	23064
The number	23064
labeled profiles and the relative tissue area occupied by labeled profiles were quantified for each image at a constant discrimination level and an average value	23078
labeled profiles	23078
the relative tissue area occupied by labeled profiles were quantified for each image at a constant discrimination level and an average value	23099
the relative tissue area	23099
profiles	23144
each image at a constant discrimination level and an average value	23173
each image	23173
a constant discrimination level and an average value	23187
a constant discrimination level	23187
an average value	23223
each section	23259
the number of labeled rubrospinal stem axons in the lateral funiculus in five randomly selected sections at 250 × final magnification	23288
the number	23288
rubrospinal stem axons in the lateral funiculus	23310
rubrospinal stem axons	23310
the lateral funiculus	23336
five randomly selected sections at 250 × final magnification	23361
five randomly selected sections	23361
250 × final magnification	23396
values describing the mean number of arborizations per labeled stem axon	23422
values	23422
the mean number of arborizations per labeled stem axon	23440
the mean number	23440
arborizations per labeled stem axon	23459
arborizations	23459
labeled stem axon	23477
Image processing Preparations	23512
a Nikon DXM1200 digital camera attached to a Leitz microscope	23565
a Nikon DXM1200 digital camera	23565
a Leitz microscope	23608
The captured images	23628
a single canvas	23675
Adobe Photoshop software	23709
The contrast and brightness	23735
optimal clarity	23788
Statistical analysis One-way analysis of variance -LRB- ANOVA -RRB- followed by a post hoc Newman -- Keuls Multiple Comparison Test	23805
Statistical analysis One-way analysis	23805
variance	23846
ANOVA	23856
a post hoc Newman -- Keuls Multiple Comparison Test	23875
a post hoc Newman	23875
Keuls Multiple Comparison Test	23893
statistical differences between the experimental groups -LRB- Prism ® , GraphPad Software , Inc ; San Diego , CA -RRB-	23946
statistical differences	23946
the experimental groups -LRB- Prism ® , GraphPad Software , Inc ; San Diego , CA -RRB-	23978
the experimental groups	23978
Prism ® , GraphPad Software	24003
Prism ®	24003
GraphPad Software	24011
Inc ; San Diego , CA	24030
Inc	24030
San Diego , CA	24035
San Diego	24035
CA	24046
Result Fig. 1 .	24052
Result Fig.	24052
1	24064
Primary culture of olfactory ensheathing cells , OEC -LRB- A -RRB- and OEC	24067
Primary culture	24067
olfactory ensheathing cells , OEC -LRB- A -RRB- and OEC	24086
olfactory ensheathing cells	24086
OEC -LRB- A -RRB- and OEC	24115
OEC -LRB- A -RRB-	24115
OEC	24115
A	24120
OEC	24127
a method of differential adhesion -LRB- B -- E -RRB- and immunomagnetic beads -LRB- F -RRB-	24145
a method	24145
differential adhesion -LRB- B -- E -RRB- and immunomagnetic beads -LRB- F -RRB-	24157
differential adhesion	24157
B -- E	24180
B	24180
E	24182
immunomagnetic beads	24189
F	24211
Cell	24215
low-affinity NGF receptors p75 -LRB- p75 -RRB- , S-100 protein -LRB- S100 -RRB- and GFAP	24242
low-affinity NGF receptors p75 -LRB- p75 -RRB-	24242
low-affinity NGF receptors p75	24242
p75	24274
S-100 protein -LRB- S100 -RRB-	24280
S-100 protein	24280
S100	24295
GFAP	24305
Cells in -LRB- E -RRB- labeled with GFP -LRB- green -RRB- and counterstainedwith p75 antibodies -LRB- red -RRB- .	24311
Cells	24311
-LRB- E -RRB- labeled with GFP -LRB- green -RRB- and counterstainedwith p75 antibodies -LRB- red -RRB-	24320
-LRB- E -RRB-	24320
GFP -LRB- green -RRB- and counterstainedwith p75 antibodies -LRB- red -RRB-	24337
GFP	24337
counterstainedwith p75 antibodies	24353
red	24388
numerous round profiles of immunomagnetic beads attached to OEC in -LRB- F -RRB-	24399
numerous round profiles	24399
immunomagnetic beads attached to OEC in -LRB- F -RRB-	24426
immunomagnetic beads	24426
OEC	24459
F	24467
Blue nuclei	24471
DAPI	24500
Scale bar , 50 μm -LRB- A -- D -RRB- , 80 μm -LRB- E -RRB- and 160 μm -LRB- F -RRB- .	24506
Scale bar	24506
50 μm -LRB- A -- D -RRB- , 80 μm -LRB- E -RRB- and 160 μm -LRB- F -RRB-	24517
50 μm -LRB- A -- D -RRB-	24517
A -- D	24524
A	24524
D	24526
80 μm -LRB- E -RRB-	24530
E	24537
160 μm -LRB- F -RRB-	24544
F	24552
Fig. 2 .	24557
Fig.	24557
2	24562
Graphs showing the proportion of cells immunostained for low-affinity NGF receptors p75 -LRB- A -RRB- and S-100 protein -LRB- B -RRB- in OEC cultures	24565
Graphs	24565
the proportion of cells immunostained for low-affinity NGF receptors p75 -LRB- A -RRB- and S-100 protein -LRB- B -RRB- in OEC cultures	24580
the proportion	24580
cells immunostained for low-affinity NGF receptors p75 -LRB- A -RRB- and S-100 protein -LRB- B -RRB- in OEC cultures	24598
cells	24598
low-affinity NGF receptors p75 -LRB- A -RRB- and S-100 protein -LRB- B -RRB-	24622
low-affinity NGF receptors p75	24622
A	24654
S-100 protein	24661
B	24676
OEC cultures	24682
a method of differential adhesion	24709
a method	24709
differential adhesion	24721
D/S -10 S medium -LRB- D/F -10 S -RRB- , DMEM-10S medium supplemented with forskolin and pituitary extract -LRB- Forskolin + PitExt -RRB- , and D/F -10 S medium supplemented with forskolin and recombinant human glial growth factor 2 -LRB- Forskolin + GGF2 -RRB-	24755
D/S -10 S medium -LRB- D/F -10 S -RRB- ,	24755
D/S -10 S medium	24755
D/F -10 S	24771
D/F	24771
-10 S	24774
forskolin and pituitary extract -LRB- Forskolin + PitExt -RRB-	24815
forskolin and pituitary extract	24815
Forskolin + PitExt	24848
Forskolin	24848
PitExt	24858
D/F -10 S medium supplemented with forskolin and recombinant human glial growth factor 2 -LRB- Forskolin + GGF2 -RRB-	24871
D/F -10 S medium	24871
forskolin and recombinant human glial growth factor 2 -LRB- Forskolin + GGF2 -RRB-	24904
forskolin	24904
recombinant human glial growth factor 2 -LRB- Forskolin + GGF2 -RRB-	24918
recombinant human glial growth factor	24918
2 -LRB- Forskolin + GGF2 -RRB-	24956
2	24956
Forskolin + GGF2	24959
Forskolin	24959
GGF2	24969
Error bars	24976
S.E.M.	24992
There	24999
no statistical differences between OEC cultured with forskolin and GGF2 for 3 and 7 weeks -LRB- PN0 .05 -RRB-	25009
no statistical differences	25009
OEC cultured with forskolin and GGF2 for 3 and 7 weeks -LRB- PN0 .05 -RRB-	25044
OEC	25044
forskolin and GGF2	25062
3 and 7 weeks -LRB- PN0 .05 -RRB-	25085
3 and 7 weeks	25085
PN0 .05	25100
Graph in -LRB- C -RRB-	25109
Graph in	25109
Graph	25109
C	25119
cumulative growth rate	25128
Population Doublings per week -LRB- Rubio et al. , 2008 -RRB-	25167
Population Doublings	25167
week -LRB- Rubio et al. , 2008 -RRB-	25192
week	25192
Rubio	25198
et al. , 2008	25204
et al.	25204
2008	25212
Fig. 3 .	25220
Fig.	25220
3	25225
Horizontal spinal cord sections	25228
low-affinity NGF receptors p75 -LRB- A -- F ; p75 , red -RRB-	25278
low-affinity NGF receptors p75	25278
A -- F ; p75 , red	25310
A -- F ; p75	25310
F	25312
red	25320
GFP-labeled OEC -LRB- A -- D , green -RRB-	25333
GFP-labeled OEC	25333
A -- D , green	25350
D , green	25352
D	25352
green	25355
Fast Blue-labeled OEC -LRB- E -- F , blue -RRB- at 3weeks -LRB- A -RRB- and8weeks -LRB- B -- F -RRB-	25366
Fast Blue-labeled OEC -LRB- E -- F , blue -RRB-	25366
Fast Blue-labeled OEC	25366
E	25389
F , blue	25391
F	25391
blue	25394
3weeks -LRB- A -RRB- and8weeks -LRB- B -- F -RRB-	25403
3weeks -LRB- A -RRB-	25403
3weeks	25403
A	25410
and8weeks -LRB- B -- F -RRB-	25412
and8weeks	25412
B -- F	25422
B	25422
F	25424
transplantation	25433
Images in -LRB- C -- D -RRB- and -LRB- F -RRB-	25450
Images in -LRB- C -- D -RRB-	25450
Images	25450
C -- D	25460
C	25460
D	25462
-LRB- F -RRB-	25469
enlarged views of the boxed areas in -LRB- B -RRB- and -LRB- E -RRB- , respectively	25477
enlarged views	25477
the boxed areas in -LRB- B -RRB- and -LRB- E -RRB- , respectively	25495
the	25495
areas	25505
-LRB- B -RRB- and -LRB- E -RRB-	25513
-LRB- B -RRB-	25513
-LRB- E -RRB-	25521
Injection sites -LRB- G -- I -RRB-	25540
Injection sites	25540
G -- I	25557
G	25557
I	25559
p75 receptors	25579
8 weeks	25596
transplantation of b-OEC ST -LRB- G -RRB- , a-OEC ST -LRB- H -RRB- and a-OEC LT -LRB- I -RRB-	25610
transplantation	25610
b-OEC ST -LRB- G -RRB- , a-OEC ST -LRB- H -RRB- and a-OEC LT -LRB- I -RRB-	25629
b-OEC ST -LRB- G -RRB-	25629
b-OEC ST	25629
G	25639
a-OEC ST -LRB- H -RRB-	25643
a-OEC ST	25643
H	25653
a-OEC LT -LRB- I -RRB-	25660
a-OEC LT	25660
I	25670
significant reduction of p75-immunoreactivity	25679
significant reduction	25679
p75-immunoreactivity	25704
I	25729
Arrows	25733
injection sites	25749
Asterisks	25766
trauma zones	25785
FB in -LRB- I -RRB-	25799
FB in	25799
FB	25799
I	25806
Fast Blue labeling	25819
Blue nuclei in -LRB- G -RRB- and -LRB- H -RRB-	25839
Blue nuclei	25839
-LRB- G -RRB- and -LRB- H -RRB-	25854
-LRB- G -RRB-	25854
-LRB- H -RRB-	25862
DAPI	25879
Scale bar , 200 μm in -LRB- A , B , E -RRB- , 50 μm in -LRB- G -- H -RRB- and 25 μm in -LRB- I -RRB- .	25885
Scale bar , 200 μm in -LRB- A , B , E -RRB- , 50 μm in -LRB- G -- H -RRB- and 25 μm in -LRB- I -RRB-	25885
Scale bar , 200 μm in -LRB- A , B , E -RRB- , 50 μm in -LRB- G -- H -RRB- and 25 μm in	25885
200 μm	25896
A , B , E	25907
50 μm	25917
G -- H	25927
G	25927
H	25929
25 μm	25936
I	25946
Fig. 4 .	25951
Fig.	25951
4	25956
Histogram showing survival of Fast Blue-labeled rubrospinal neurons at 8 weeks after cervical spinal cord injury -LRB- A -RRB- and the density of BDA-labeled rubrospinal stem axons in the dorsolateral funiculus -LRB- B -RRB- , the density of rubrospinal terminal arborizations in the gray matter -LRB- C -RRB- and the ratio between the density of rubrospinal arborizations and the axons in the dorsolateral funiculus -LRB- D -RRB- at 13 weeks after cervical spinal cord injury -LRB- SCI -RRB- and following transplantation of OEC .	25959
Histogram	25959
survival of Fast Blue-labeled rubrospinal neurons at 8 weeks	25977
survival	25977
Fast Blue-labeled rubrospinal neurons at 8 weeks	25989
Fast Blue-labeled rubrospinal neurons	25989
8 weeks	26030
cervical spinal cord injury -LRB- A -RRB- and the density of BDA-labeled rubrospinal stem axons in the dorsolateral funiculus -LRB- B -RRB- , the density of rubrospinal terminal arborizations in the gray matter -LRB- C -RRB- and the ratio between the density of rubrospinal arborizations and the axons in the dorsolateral funiculus -LRB- D -RRB-	26044
cervical spinal cord injury -LRB- A -RRB-	26044
cervical spinal cord injury	26044
A	26073
the density of BDA-labeled rubrospinal stem axons in the dorsolateral funiculus -LRB- B -RRB- , the density of rubrospinal terminal arborizations in the gray matter -LRB- C -RRB- and the ratio between the density of rubrospinal arborizations and the axons in the dorsolateral funiculus -LRB- D -RRB-	26080
the density	26080
BDA-labeled rubrospinal stem axons in the dorsolateral funiculus -LRB- B -RRB- , the density of rubrospinal terminal arborizations in the gray matter -LRB- C -RRB- and the ratio between the density of rubrospinal arborizations and the axons in the dorsolateral funiculus -LRB- D -RRB-	26095
BDA-labeled rubrospinal stem axons	26095
the dorsolateral funiculus	26133
B	26161
the density of rubrospinal terminal arborizations in the gray matter -LRB- C -RRB- and the ratio between the density of rubrospinal arborizations	26165
the density	26165
rubrospinal terminal arborizations in the gray matter -LRB- C -RRB- and the ratio between the density of rubrospinal arborizations	26180
rubrospinal terminal arborizations in the gray matter -LRB- C -RRB-	26180
rubrospinal terminal arborizations	26180
the gray matter -LRB- C -RRB-	26218
the gray matter	26218
C	26235
the ratio between the density of rubrospinal arborizations	26242
the ratio	26242
the density of rubrospinal arborizations	26260
the density	26260
rubrospinal arborizations	26275
the axons in the dorsolateral funiculus -LRB- D -RRB-	26305
the axons	26305
the dorsolateral funiculus -LRB- D -RRB-	26318
the dorsolateral funiculus	26318
D	26346
13 weeks after cervical spinal cord injury -LRB- SCI -RRB- and following transplantation of OEC	26352
13 weeks after cervical spinal cord injury -LRB- SCI -RRB-	26352
13 weeks	26352
cervical spinal cord injury -LRB- SCI -RRB-	26367
cervical spinal cord injury	26367
SCI	26396
following transplantation of OEC	26405
following transplantation	26405
OEC	26434
Control	26439
untreated rats	26457
1 week after Fast Bluelabeling -LRB- A -RRB- or normal uninjured rats at 1 week after BDA-labeling -LRB- B -- D -RRB-	26475
1 week after Fast Bluelabeling -LRB- A -RRB-	26475
1 week	26475
Fast Bluelabeling -LRB- A -RRB-	26488
Fast Bluelabeling	26488
A	26507
normal uninjured rats at 1 week after BDA-labeling -LRB- B -- D -RRB-	26513
normal uninjured rats	26513
1 week after BDA-labeling -LRB- B -- D -RRB-	26538
1 week	26538
BDA-labeling -LRB- B -- D -RRB-	26551
BDA-labeling	26551
B -- D	26565
B	26565
D	26567
Error bars	26571
S.E.M.	26587
A	26598
Pb0 .05	26602
* -LRB- control vs. b-OEC ST ; a-OEC ST vs. SCI and b-OEC ST -RRB- and Pb0 .001 is indicated by # -LRB- control vs. SCI , a-OEC ST and a-OEC LT ; b-OEC ST vs. SCI and a-OEC LT ; a-OEC ST vs. a-OEC LT -RRB-	26625
* -LRB- control vs. b-OEC ST ; a-OEC ST vs. SCI and b-OEC ST -RRB-	26625
*	26625
control vs. b-OEC ST ; a-OEC ST vs. SCI and b-OEC ST	26628
control	26628
b-OEC ST ; a-OEC ST vs. SCI and b-OEC ST	26640
b-OEC ST	26640
a-OEC ST vs. SCI and b-OEC ST	26650
a-OEC ST	26650
SCI and b-OEC ST	26663
Pb0 .001 is indicated by # -LRB- control vs. SCI , a-OEC ST and a-OEC LT ; b-OEC ST vs. SCI and a-OEC LT ; a-OEC ST vs. a-OEC LT -RRB-	26685
Pb0 .001	26685
# -LRB- control vs. SCI , a-OEC ST and a-OEC LT ; b-OEC ST vs. SCI and a-OEC LT ; a-OEC ST vs. a-OEC LT -RRB-	26709
#	26709
control vs. SCI , a-OEC ST and a-OEC LT ; b-OEC ST vs. SCI and a-OEC LT ; a-OEC ST vs. a-OEC LT	26712
control	26712
SCI , a-OEC ST and a-OEC LT ; b-OEC ST vs. SCI and a-OEC LT ; a-OEC ST vs. a-OEC LT	26724
SCI	26724
a-OEC ST and a-OEC LT ; b-OEC ST vs. SCI and a-OEC LT ; a-OEC ST vs. a-OEC LT	26729
a-OEC ST and a-OEC LT	26729
a-OEC	26729
ST and a-OEC LT	26735
b-OEC ST vs. SCI and a-OEC LT	26752
b-OEC ST	26752
SCI and a-OEC LT	26765
SCI	26765
a-OEC LT	26773
a-OEC ST vs. a-OEC LT	26783
a-OEC ST	26783
a-OEC LT	26796
B	26811
Pb0 .05	26815
* -LRB- b-OEC ST vs. SCI -RRB- and Pb0 .001 is indicated by # -LRB- control and a-OEC ST vs. SCI , b-OEC ST and a-OEC LT -RRB-	26838
* -LRB- b-OEC ST vs. SCI -RRB-	26838
*	26838
b-OEC ST vs. SCI	26841
b-OEC ST	26841
SCI	26854
Pb0 .001 is indicated by # -LRB- control and a-OEC ST vs. SCI , b-OEC ST and a-OEC LT -RRB-	26863
Pb0 .001	26863
#	26887
control and a-OEC ST	26890
control	26890
a-OEC ST	26902
SCI , b-OEC ST and a-OEC LT	26915
SCI	26915
b-OEC ST and a-OEC LT	26920
C	26948
Pb0 .05	26952
* -LRB- b-OEC ST vs. control , SCI and a-OEC LT -RRB- and Pb0 .001 is indicated by # -LRB- a-OEC ST vs. control , SCI , b-OEC-ST and a-OEC LT -RRB-	26975
* -LRB- b-OEC ST vs. control , SCI and a-OEC LT -RRB-	26975
*	26975
b-OEC ST vs. control , SCI and a-OEC LT	26978
b-OEC ST	26978
control , SCI and a-OEC LT	26991
control	26991
SCI	27000
a-OEC LT	27008
Pb0 .001 is indicated by # -LRB- a-OEC ST vs. control , SCI , b-OEC-ST and a-OEC LT -RRB-	27022
Pb0 .001	27022
# -LRB- a-OEC ST vs. control , SCI , b-OEC-ST and a-OEC LT -RRB-	27046
#	27046
a-OEC ST vs. control , SCI , b-OEC-ST and a-OEC LT	27049
a-OEC ST	27049
control , SCI , b-OEC-ST and a-OEC LT	27062
control	27062
SCI	27071
b-OEC-ST	27076
a-OEC LT	27089
D	27104
Pb0 .05	27108
* -LRB- a-OEC ST vs. SCI and a-OEC LT -RRB- and Pb0 .001 is indicated by # -LRB- control vs. experiment ; b-OEC ST vs. SCI , a-OEC ST and a-OEC LT -RRB-	27131
* -LRB- a-OEC ST vs. SCI and a-OEC LT -RRB-	27131
*	27131
a-OEC ST vs. SCI and a-OEC LT	27134
a-OEC ST vs. SCI and a-OEC	27134
a-OEC ST	27134
SCI and a-OEC	27147
LT	27161
Pb0 .001 is indicated by # -LRB- control vs. experiment ; b-OEC ST vs. SCI , a-OEC ST and a-OEC LT -RRB-	27169
Pb0 .001	27169
# -LRB- control vs. experiment ; b-OEC ST vs. SCI , a-OEC ST and a-OEC LT -RRB-	27193
#	27193
control vs. experiment ; b-OEC ST vs. SCI , a-OEC ST and a-OEC LT	27196
control vs. experiment ; b-OEC ST vs. SCI , a-OEC	27196
control vs. experiment	27196
control	27196
experiment	27208
b-OEC ST vs. SCI , a-OEC	27220
b-OEC ST	27220
SCI , a-OEC	27233
ST and a-OEC LT	27244
Fig. 5 .	27263
Fig.	27263
5	27268
Horizontal spinal cord sections	27271
pan-neurofilament	27321
regeneration in the trauma zone -LRB- asterisks -RRB-	27351
regeneration	27351
the trauma zone -LRB- asterisks -RRB-	27367
the trauma zone	27367
asterisks	27384
13 weeks after cervical SCI and following transplantation of b-OEC ST -LRB- A -RRB- , a-OEC LT -LRB- B -RRB- and a-OEC ST -LRB- E and F -RRB-	27398
13 weeks after cervical SCI	27398
13 weeks	27398
cervical SCI	27413
following transplantation of b-OEC ST -LRB- A -RRB- , a-OEC LT -LRB- B -RRB- and a-OEC ST -LRB- E and F -RRB-	27430
following transplantation	27430
b-OEC ST -LRB- A -RRB- , a-OEC LT -LRB- B -RRB- and a-OEC ST -LRB- E and F -RRB-	27459
b-OEC ST -LRB- A -RRB-	27459
b-OEC ST	27459
A	27469
a-OEC LT -LRB- B -RRB-	27473
a-OEC LT	27473
B	27483
a-OEC ST -LRB- E and F -RRB-	27490
a-OEC ST	27490
E and F	27500
E	27500
F	27506
areas in -LRB- A -RRB- , -LRB- B -RRB-	27516
areas	27516
-LRB- A -RRB- , -LRB- B -RRB-	27525
-LRB- A -RRB-	27525
B	27531
-LRB- E -RRB- and -LRB- F -RRB-	27535
-LRB- E -RRB-	27535
-LRB- F -RRB-	27543
-LRB- C -RRB- , -LRB- D -RRB- , -LRB- G -RRB- and -LRB- H -RRB-	27563
-LRB- C -RRB-	27563
-LRB- D -RRB-	27568
-LRB- G -RRB-	27573
-LRB- H -RRB-	27581
numerous regenerating fibers	27605
E -- F	27638
E	27638
F	27640
a-OEC ST transplantation	27649
Scale bar , 200 μm .	27675
Scale bar	27675
200 μm	27686
Fig. 6 .	27695
Fig.	27695
6	27700
Horizontal spinal cord sections showing BDA-labeled rubrospinal axons -LRB- A -- C -RRB- , CGRP-immunolabeled axons -LRB- D -RRB- and raphaespinal axons immunostained for serotonin -LRB- E -- I -RRB- at 13 weeks after cervical SCI and following transplantation of a-OEC ST. Boxed areas in -LRB- A -RRB- and -LRB- E -RRB-	27703
Horizontal spinal cord sections	27703
BDA-labeled rubrospinal axons -LRB- A -- C -RRB- , CGRP-immunolabeled axons -LRB- D -RRB- and raphaespinal axons immunostained for serotonin -LRB- E -- I -RRB-	27743
BDA-labeled rubrospinal axons -LRB- A -- C -RRB- , CGRP-immunolabeled axons -LRB- D -RRB- and raphaespinal axons immunostained for serotonin	27743
A -- C	27774
A	27774
C	27776
D	27806
raphaespinal axons	27813
serotonin	27850
E -- I	27861
E	27861
I	27863
13 weeks after cervical SCI	27869
13 weeks	27869
cervical SCI	27884
transplantation of a-OEC	27911
transplantation	27911
a-OEC	27930
ST. Boxed areas	27936
-LRB- A -RRB- and -LRB- E -RRB-	27955
-LRB- A -RRB-	27955
-LRB- E -RRB-	27963
enlarged in -LRB- B -- C -RRB- and -LRB- F -- I -RRB-	27971
enlarged in -LRB- B -- C -RRB- and	27971
B -- C	27984
B	27984
C	27986
F -- I	27994
F	27994
I	27996
rubrospinal and raphaespinal axons	28027
the lesion site	28071
Asterisks	28088
trauma zones	28107
Images in -LRB- A -- C -RRB-	28121
Images in	28121
Images	28121
A -- C	28132
A	28132
C	28134
cresyl violet	28161
Scale bar , 200 μm .	28176
Scale bar	28176
200 μm	28187
Olfactory ensheathing cell culture Primary OEC cultures in the present study contained about 35 -- 40 % of cells immunopositive for low-affinity NGF receptor p75 -LRB- Fig. 1A -RRB- .	28196
Olfactory ensheathing cell culture Primary OEC cultures in the present study contained about 35	28196
Olfactory ensheathing cell culture	28196
Primary OEC cultures in the present study	28231
Primary OEC cultures	28231
the present study	28255
35	28289
40 % of cells immunopositive for low-affinity NGF receptor p75 -LRB- Fig. 1A -RRB-	28292
40 %	28292
cells immunopositive for low-affinity NGF receptor p75 -LRB- Fig. 1A -RRB-	28299
cells immunopositive for low-affinity NGF receptor p75	28299
cells	28299
low-affinity NGF receptor p75	28324
Fig. 1A	28355
purification with the method of differential adhesion	28371
purification	28371
the method of differential adhesion	28389
the method	28389
differential adhesion	28403
93 -- 95 % of cells in cultures	28426
93 -- 95 %	28426
93	28426
cells in cultures	28436
cells	28436
cultures	28445
p75 receptors , S-100 protein and GFAP -LRB- Fig. 1B , C , D -RRB-	28477
p75 receptors	28477
S-100 protein and GFAP -LRB- Fig. 1B , C , D -RRB-	28492
S-100 protein and GFAP	28492
Fig. 1B	28516
C	28524
D	28526
The majority of non-OEC cells	28530
The majority	28530
non-OEC cells	28546
Thy 1.1 - positive cells	28565
Thy 1.1	28565
positive cells	28574
our attempts to maintain pure long-term cultures of a-OEC for intraspinal transplantation	28593
pure long-term cultures of a-OEC	28618
pure long-term cultures	28618
a-OEC	28645
intraspinal transplantation	28655
we	28684
well known protocols using growth medium D/F -10 S alone or with DMEM-10S supplemented with forskolin and pituitary extract	28696
well known protocols	28696
growth medium D/F -10 S alone or with DMEM-10S supplemented with forskolin and pituitary extract	28723
growth medium D/F	28723
-10 S	28740
DMEM-10S	28759
forskolin and pituitary extract	28786
forskolin	28786
pituitary extract	28800
D/F -10 S medium	28824
cultures	28839
non-OEC cells	28873
1 week -LRB- Fig. 2 -RRB- and the proportion of p75-positive and S-100	28901
1 week -LRB- Fig. 2 -RRB-	28901
1 week	28901
Fig. 2	28909
the proportion of p75-positive and S-100	28921
the proportion	28921
p75-positive and S-100	28939
p75-positive	28939
S-100	28956
positive cells	28963
42 % -LRB- Pb0 .001 -RRB- and 35 % -LRB- Pb0 .001 -RRB-	28993
42 %	28993
Pb0 .001	28998
35 %	29011
Pb0 .001	29016
DMEM-10S medium supplemented with forskolin and pituitary extract	29045
DMEM-10S medium	29045
forskolin and pituitary extract	29079
forskolin	29079
pituitary extract	29093
the proportion of p75 - and S-100-positive cells	29111
the proportion	29111
p75 - and S-100-positive cells	29129
80 -- 90 % during the first week	29175
80	29175
90 % during the first week	29178
90 %	29178
the first week	29189
purification	29210
2 weeks in culture	29234
2 weeks	29234
culture	29245
it	29253
15 -- 18 % -LRB- Pb0 .0001 ; Fig. 2 -RRB-	29279
15 -- 18 %	29279
15	29279
Pb0 .0001 ; Fig. 2	29287
Pb0 .0001	29287
Fig. 2	29297
D/F -10 S medium supplemented with forskolin and recombinant human GGF2	29320
D/F -10 S medium	29320
forskolin and recombinant human GGF2	29353
forskolin	29353
recombinant human GGF2	29367
90 -- 95 % pure a-OEC for at least 11 weeks -LRB- Fig. 2 -RRB-	29401
90	29401
95 % pure a-OEC for at least 11 weeks -LRB- Fig. 2 -RRB-	29404
95 % pure a-OEC	29404
at least 11 weeks -LRB- Fig. 2 -RRB-	29423
at least 11 weeks	29423
Fig. 2	29442
Purification of primary cultures with immunomagnetic beads	29451
Purification	29451
primary cultures with immunomagnetic beads	29467
primary cultures	29467
immunomagnetic beads	29489
most cases	29522
80 % OEC purity	29536
purification	29570
numerous Dynabeads	29584
the cell surface -LRB- Fig. 1F -RRB-	29624
the cell surface	29624
Fig. 1F	29642
The number of attached Dynabeads	29652
The number	29652
attached Dynabeads	29666
2 weeks in culture	29703
2 weeks	29703
culture	29714
they	29726
spinal cord sections	29753
13 weeks	29774
transplantation -LRB- data not shown -RRB-	29789
transplantation	29789
data not shown	29806
data	29806
contrast to a-OEC	29826
contrast	29826
a-OEC	29838
we	29845
all growth mediums tested	29864
all growth mediums	29864
it	29891
80 % pure b-OEC cultures for more than 2 -- 3 weeks due to contamination with Thy 1.1-positive and p75 - / S100-negative non-OEC cells	29923
80 % pure b-OEC cultures	29923
more than 2 -- 3 weeks due to contamination with Thy 1.1-positive and p75 - / S100-negative non-OEC cells	29951
3 weeks	29963
contamination with Thy 1.1-positive and p75	29978
contamination	29978
Thy 1.1-positive and p75	29997
Thy 1.1-positive	29997
p75	30018
Distribution of olfactory ensheathing cells Three weeks	30052
Distribution	30052
olfactory ensheathing cells	30068
Three weeks	30096
transplantation	30114
numerous GFP-labeled OEC -LRB- Fig. 1E -RRB-	30131
numerous GFP-labeled OEC	30131
Fig. 1E	30157
the injection sites rostral and caudal	30182
the injection sites	30182
the spinal cord hemisection	30224
the trauma zone -LRB- Fig. 3A -RRB-	30259
the trauma zone	30259
Fig. 3A	30276
The trauma zone	30286
both injection sites	30321
narrow tract formed by transplanted OEC	30345
narrow tract	30345
transplanted OEC	30368
we	30395
any OEC migration rostral and caudal	30411
any OEC migration rostral	30411
caudal	30441
the injection sites	30453
The number of GFP-OEC	30474
The number	30474
GFP-OEC	30488
8 weeks post-operatively -LRB- Fig. 3A and B -RRB-	30520
8 weeks post-operatively	30520
8 weeks	30520
Fig. 3A and B	30546
Fig. 3A	30546
B	30558
The changes	30562
the trauma zone where only single GFP-positive cells could be detected -LRB- compare Fig. 3C and D -RRB-	30595
the trauma zone	30595
only single GFP-positive cells	30617
Fig. 3C and D	30675
Fig. 3C	30675
D	30687
the reduction in GFP-OEC number	30697
the reduction	30697
GFP-OEC number	30714
down regulation of GFP expression -LRB- Vroemen et al. , 2005 -RRB-	30745
down regulation	30745
GFP expression -LRB- Vroemen et al. , 2005 -RRB-	30764
GFP expression	30764
Vroemen	30780
et al. , 2005	30788
et al.	30788
2005	30796
we	30803
Fast Blue-labeled OEC -LRB- Pettersson et al. , 2010 -RRB-	30824
Fast Blue-labeled OEC	30824
Pettersson	30847
et al. , 2010	30858
et al.	30858
2010	30866
distribution of these cells at 8 weeks after SCI	30887
distribution	30887
these cells at 8 weeks after SCI	30903
these cells	30903
8 weeks after SCI	30918
8 weeks	30918
SCI	30932
GFP-OEC -LRB- Fig. 3B and E -RRB- with a predominant concentration of labeled cells at the injection sites -LRB- Fig. 3F -RRB-	30951
GFP-OEC -LRB- Fig. 3B and E -RRB-	30951
GFP-OEC	30951
Fig. 3B and E	30960
Fig. 3B	30960
E	30972
a predominant concentration of labeled cells at the injection sites	30980
a predominant concentration	30980
labeled cells at the injection sites	31011
labeled cells	31011
the injection sites	31028
Fig. 3F	31049
Immunostaining with p75	31059
Immunostaining	31059
p75	31079
p75 - immunoreactivity	31106
p75	31106
immunoreactivity	31111
labeled cells in the transplantation sites	31143
labeled cells	31143
the transplantation sites	31160
the trauma zone	31193
it	31209
the areas occupied by GFPand Fast Blue-positive OEC -LRB- Fig. 3A , B , E -RRB-	31223
the areas	31223
GFPand Fast Blue-positive OEC -LRB- Fig. 3A , B , E -RRB-	31245
GFPand Fast Blue-positive OEC	31245
Fig. 3A	31276
B	31284
E	31286
addition	31293
animals transplanted with short-term cultured OEC -LRB- OEC ST -RRB-	31303
animals	31303
short-term cultured OEC	31329
short-term	31329
OEC	31349
OEC	31354
larger areas of p75-immunostaining	31366
larger areas	31366
p75-immunostaining	31382
the injection sites -LRB- Fig. 3G , H -RRB- than animals with long-term cultured OEC -LRB- OEC LT ; Fig. 3I -RRB-	31404
the injection sites -LRB- Fig. 3G , H -RRB-	31404
the injection sites	31404
Fig. 3G , H	31425
Fig. 3G	31425
H	31433
animals with long-term cultured OEC	31441
animals	31441
long-term cultured OEC	31454
long-term	31454
OEC	31473
OEC LT ; Fig. 3I	31478
OEC LT	31478
Fig. 3I	31486
Survival of rubrospinal neurons	31496
Survival	31496
rubrospinal neurons	31508
the control animals 1 week	31531
the control animals	31531
1 week	31551
Fast Blue application to the lumbar spinal cord	31564
Fast Blue application	31564
the lumbar spinal cord	31589
the red nucleus	31613
1704 ± 58 labeled neuronal profiles with nucleus -LRB- mean ± S.E.M. -RRB-	31639
1704 ± 58	31639
1704	31639
58	31644
neuronal profiles	31655
nucleus	31678
mean ± S.E.M.	31687
mean ±	31687
S.E.M.	31692
Most of the labeled neurons	31701
Most	31701
the labeled neurons	31709
the ventral portion of the magnocellular and parvicellular regions of the red nucleus	31745
the ventral portion	31745
the magnocellular and parvicellular regions of the red nucleus	31768
the magnocellular and parvicellular regions	31768
the red nucleus	31815
8 weeks after cervical C4 SCI	31835
8 weeks	31835
cervical C4 SCI	31849
only 54 % of labeled rubrospinal neurons	31865
only 54 %	31865
labeled rubrospinal neurons	31877
the nucleus -LRB- Pb0 .001 ; Fig. 4A -RRB-	31917
the nucleus	31917
Pb0 .001 ; Fig. 4A	31930
Pb0 .001	31930
Fig. 4A	31939
most of them	31952
most	31952
them	31960
significant cell atrophy -LRB- data not shown -RRB-	31975
significant cell atrophy	31975
data not shown	32001
data	32001
Transplantation of b-OEC	32018
Transplantation	32018
b-OEC	32037
ST increased survival rate to 84 % -LRB- Pb0 .001 ; b-OEC ST vs. SCI ; Fig. 4A -RRB- whereas transplantation of a-OEC ST protected 69 % of the rubrospinal neurons	32043
ST	32043
survival rate to 84 % -LRB- Pb0 .001 ; b-OEC ST vs. SCI ; Fig. 4A -RRB-	32056
survival rate	32056
84 % -LRB- Pb0 .001 ; b-OEC ST vs. SCI ; Fig. 4A -RRB-	32073
84 %	32073
Pb0 .001 ; b-OEC ST vs. SCI ; Fig. 4A	32078
Pb0 .001	32078
b-OEC ST vs. SCI ; Fig. 4A	32087
b-OEC ST vs. SCI	32087
b-OEC ST	32087
SCI	32100
Fig. 4A	32105
Fig.	32105
4A	32110
transplantation of a-OEC ST	32122
transplantation	32122
a-OEC ST	32141
69 % of the rubrospinal neurons	32160
69 %	32160
the rubrospinal neurons	32167
Pb0	32192
.05 ; a-OEC ST vs. SCI ; Fig. 4A	32195
.05	32195
a-OEC ST vs. SCI	32200
a-OEC ST	32200
SCI	32213
Fig. 4A	32218
contrast	32231
transplantation of a-OEC LT	32241
transplantation	32241
a-OEC LT	32260
no effect on retrograde cell death	32273
no effect	32273
retrograde cell death	32286
SCI -LRB- Fig. 4A -RRB-	32314
SCI	32314
Fig. 4A	32319
Axonal	32329
regeneration Quantification of BDA-labeled axonal profiles	32350
regeneration Quantification	32350
BDA-labeled axonal profiles	32381
the C2 cervical dorsolateral funiculus at 13 weeks after SCI revealed that the density of rubrospinal axons was significantly reduced to 30 % of normal control	32412
the C2	32412
cervical dorsolateral funiculus at 13 weeks after SCI	32419
cervical dorsolateral funiculus	32419
13 weeks after SCI	32454
13 weeks	32454
SCI	32469
the density of rubrospinal axons	32487
the density	32487
rubrospinal axons	32502
30 % of normal control	32549
30 %	32549
normal control	32556
Pb0 .001 ; Fig. 4B	32572
Pb0 .001	32572
Fig. 4B	32581
comparison with SCI	32594
comparison	32594
SCI	32610
transplantation of a-OEC LT	32615
transplantation	32615
a-OEC LT	32634
no effects -LRB- PN0 .05 ; Fig. 4B -- D -RRB-	32647
no effects	32647
PN0 .05	32659
Fig. 4B -- D	32667
Fig. 4B	32667
D	32675
contrast	32682
transplantation b-OEC ST	32692
transplantation b-OEC	32692
moderate increase of the density of rubrospinal stem axons	32725
moderate increase	32725
the density of rubrospinal stem axons	32746
the density	32746
rubrospinal stem axons	32761
the dorsolateral funiculus -LRB- Pb0 .05 ; Fig. 4B -RRB-	32791
the dorsolateral funiculus	32791
Pb0 .05 ; Fig. 4B	32819
Pb0 .05	32819
Fig. 4B	32827
the same time	32844
the density of terminal arborizations in the gray matter -LRB- Pb0 .05 ; Fig. 4C -RRB-	32867
the density	32867
terminal arborizations in the gray matter -LRB- Pb0 .05 ; Fig. 4C -RRB-	32882
terminal arborizations	32882
the gray matter -LRB- Pb0 .05 ; Fig. 4C -RRB-	32908
the gray matter	32908
Pb0 .05 ; Fig. 4C	32925
Pb0 .05	32925
Fig. 4C	32933
Transplantation of a-OEC ST	32943
Transplantation	32943
a-OEC ST	32962
the density of rubrospinal stemaxons	32980
the density	32980
rubrospinal stemaxons	32995
84 % of control values -LRB- Pb0 .001 ; Fig. 4B -RRB-	33020
84 %	33020
control values -LRB- Pb0 .001 ; Fig. 4B -RRB-	33027
control values	33027
Pb0 .001 ; Fig. 4B	33043
Pb0 .001	33043
Fig. 4B	33052
156 %	33078
the density of rubrospinal terminations	33083
the density	33083
rubrospinal terminations	33098
lamina V -LRB- Pb0 .001 ; a-OEC ST vs. control ; Fig. 4C -RRB-	33126
lamina V	33126
Pb0 .001 ; a-OEC ST vs. control ; Fig. 4C	33136
Pb0 .001	33136
a-OEC ST vs. control ; Fig. 4C	33145
a-OEC ST vs. control	33145
a-OEC ST	33145
control	33158
Fig. 4C	33167
Fig.	33167
4C	33172
the number of labeled arborizations in the gray matter to the number of labeled rubrospinal axons in the dorsolateral funiculus	33201
the number	33201
arborizations in the gray matter	33223
arborizations	33223
the gray matter	33240
the number of labeled rubrospinal axons in the dorsolateral funiculus	33259
the number	33259
rubrospinal axons in the dorsolateral funiculus	33281
rubrospinal axons	33281
the dorsolateral funiculus	33302
a significant decrease in the number of arborizations per stem axon	33330
a significant decrease	33330
the number of arborizations per stem axon	33356
the number	33356
arborizations per stem axon	33370
arborizations	33370
stem axon	33388
transplantation of both b-OEC ST -LRB- Pb0 .001 ; Fig. 4D -RRB- and a-OEC ST -LRB- Pb0 .05 ; Fig. 4D -RRB-	33414
transplantation	33414
both b-OEC ST -LRB- Pb0 .001 ; Fig. 4D -RRB- and a-OEC ST -LRB- Pb0 .05 ; Fig. 4D -RRB-	33433
both b-OEC ST	33433
Pb0 .001 ; Fig. 4D	33448
Pb0 .001	33448
Fig. 4D	33457
a-OEC ST	33470
Pb0 .05 ; Fig. 4D	33480
Pb0 .05	33480
Fig. 4D	33488
It	33498
a significant neuroprotective effect on red nucleus neurons	33532
a significant neuroprotective effect	33532
red nucleus neurons	33572
transplantation of short-term cultured OEC	33593
transplantation	33593
short-term cultured OEC	33612
short-term	33612
OEC	33632
rubrospinal terminals rostral	33678
the injury site	33711
13 weeks after SCI	33731
13 weeks	33731
SCI	33746
pan-neurofilament	33751
panNF	33770
immunolabeling	33777
only single nerve fibers	33801
the lesion site	33829
BDA injections into the red nucleus	33846
BDA injections	33846
the red nucleus	33866
rubrospinal axons	33908
the rostral border of the trauma zone	33937
the rostral border	33937
the trauma zone	33959
their direction	34001
parallel	34029
the scar tissue towards the contralateral gray matter -LRB- data not shown -RRB-	34041
the scar tissue	34041
the contralateral gray matter -LRB- data not shown -RRB-	34065
the contralateral gray matter	34065
data not shown	34096
data	34096
Surprisingly and despite the marked survival effect on rubrospinal neurons , transplantation of b-OEC ST	34113
Surprisingly and despite the marked survival effect	34113
the marked survival	34138
rubrospinal neurons , transplantation of b-OEC ST	34168
rubrospinal neurons	34168
transplantation of b-OEC ST	34189
transplantation	34189
b-OEC ST	34208
regrowth neither of panNF-immunolabeled nerve fibers nor rubrospinal axons -LRB- Fig. 5A , C -RRB-	34228
regrowth neither of panNF-immunolabeled nerve fibers	34228
regrowth	34228
panNF-immunolabeled nerve fibers	34248
rubrospinal axons -LRB- Fig. 5A , C -RRB-	34285
rubrospinal axons	34285
Fig. 5A , C	34304
Fig. 5A	34304
C	34312
The same negative results	34316
a-OEC LT -LRB- Fig. 5B , D -RRB-	34366
a-OEC LT	34366
Fig. 5B , D	34376
Fig. 5B	34376
D	34384
contrast , at 8 -- 13 weeks after transplantation of a-OEC ST	34391
contrast	34391
at 8 -- 13 weeks after transplantation of a-OEC ST	34401
at 8	34401
13 weeks after transplantation of a-OEC ST	34406
13 weeks	34406
transplantation of a-OEC ST	34421
transplantation	34421
a-OEC ST	34440
numerous panNF-positive fibers	34450
the lesion site -LRB- Fig. 5E , G -RRB-	34489
the lesion site	34489
Fig. 5E , G	34506
Fig. 5E	34506
G	34514
the trauma zone -LRB- Fig. 5F , H -RRB-	34537
the trauma zone	34537
Fig. 5F , H	34554
Fig. 5F	34554
H	34562
BDA-labeled rubrospinal axons -LRB- Fig. 6A -- C -RRB- and serotonin-positive raphaespinal axons -LRB- Fig. 6E -- I -RRB-	34566
BDA-labeled rubrospinal axons -LRB- Fig. 6A -- C -RRB-	34566
BDA-labeled rubrospinal axons	34566
Fig. 6A -- C	34597
Fig. 6A	34597
C	34605
serotonin-positive raphaespinal axons -LRB- Fig. 6E -- I -RRB-	34612
serotonin-positive raphaespinal axons	34612
Fig. 6E -- I	34651
Fig. 6E	34651
I	34659
the injury site	34670
the lateral border	34692
1500 μm in the white and gray matter of the distal spinal cord	34735
1500 μm	34735
the white and gray matter of the distal spinal cord	34746
the white and gray matter	34746
the distal spinal cord	34775
Sensory axons immunostained for calcitonin gene-related peptide -LRB- CGRP -RRB-	34799
Sensory axons	34799
calcitonin gene-related peptide	34831
CGRP	34864
the trauma zone -LRB- Fig. 6D -RRB-	34895
the trauma zone	34895
Fig. 6D	34912
the method of culture preparation	34928
the method	34928
culture preparation	34942
growth-promoting effect of OEC	34978
growth-promoting effect	34978
OEC	35005
intraspinal transplantation	35015
Discussion The present study	35045
Discussion	35045
The present study	35056
the age of cells in culture and the method of cell purification	35085
the age	35085
cells in culture and the method of cell purification	35096
cells in culture	35096
cells	35096
culture	35105
the method of cell purification	35117
the method	35117
cell purification	35131
the neuroprotective and growth-promoting effects of OEC transplants	35165
the neuroprotective and growth-promoting effects	35165
OEC transplants	35217
purified OEC	35243
several months in culture	35278
several months	35278
culture	35296
their p75 and S100 immunoreactivity	35319
only short-term cultured cells	35356
only short-term	35356
cells	35381
massive retrograde cell death in the red nucleus	35398
massive retrograde cell death	35398
the red nucleus	35431
rubrospinal terminals	35474
cervical spinal cord injury	35502
Long-term cultured OEC	35531
Long-term	35531
OEC	35550
no effect on neuronal survival and regeneration	35558
no effect	35558
neuronal survival and regeneration	35571
p75 immunoreactivity	35611
the injection sites	35656
short-term cultured OEC purified with a method of differential cell adhesion and with immunomagnetic beads	35691
short-term	35691
OEC purified with a method of differential cell adhesion and with immunomagnetic beads	35711
OEC	35711
a method of differential cell adhesion	35729
a method	35729
differential cell adhesion	35741
immunomagnetic beads	35777
different effects on axonal growth	35802
different effects	35802
axonal growth	35823
OEC separated with Dynabeads -LRB- b-OEC -RRB-	35838
OEC	35838
Dynabeads	35857
b-OEC	35868
regrowth	35893
the lesion site	35909
the number of rubrospinal fibers in the white matter rostral	35939
the number	35939
rubrospinal fibers in the white matter rostral	35953
rubrospinal fibers	35953
the white matter rostral	35975
the hemisection	36003
contrast	36023
OEC	36033
a method of differential adhesion -LRB- a-OEC -RRB-	36051
a method	36051
differential adhesion -LRB- a-OEC -RRB-	36063
differential adhesion	36063
a-OEC	36086
growth	36105
the descending rubrospinal and raphaespinal tracts	36117
the descending rubrospinal	36117
raphaespinal tracts	36148
the sensory CGRPpositive fibers	36177
addition	36213
intraspinal transplantation	36229
OEC	36266
very limited migration	36277
the injection sites	36325
the trauma zone	36352
accordance with previous report -LRB- Lu et al. , 2006 -RRB-	36381
accordance	36381
previous report -LRB- Lu et al. , 2006 -RRB-	36397
previous report	36397
Lu	36414
et al. , 2006	36417
et al.	36417
2006	36425
the trauma zone	36432
both injection sites	36467
narrow tract formed by transplanted OEC	36491
narrow tract	36491
transplanted OEC	36514
Factors determining the outcome of OEC transplantation Transplantation of OEC	36532
Factors	36532
the outcome of OEC transplantation Transplantation of OEC	36552
the outcome	36552
OEC transplantation Transplantation of OEC	36567
OEC transplantation Transplantation	36567
OEC	36606
axonal regeneration , myelination and neuronal survival in different experimental models of spinal cord injury -LRB- Fouad et al. , 2009a ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 -RRB-	36636
axonal regeneration , myelination and neuronal survival	36636
different experimental models of spinal cord injury -LRB- Fouad et al. , 2009a ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 -RRB-	36694
different experimental models	36694
spinal cord injury -LRB- Fouad et al. , 2009a ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009 -RRB-	36727
spinal cord injury	36727
Fouad et al. , 2009a ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009	36747
Fouad	36747
et al. , 2009a ; Kocsis et al. , 2009 ; Lindsay et al. , 2010 ; Munoz-Quiles et al. , 2009 ; Radtke and Wewetzer , 2009	36753
et al. , 2009a	36753
et al.	36753
2009a	36761
Kocsis et al. , 2009	36768
Kocsis	36768
et al. , 2009	36775
et al.	36775
2009	36783
Lindsay et al. , 2010	36789
Lindsay	36789
et al. , 2010	36797
et al.	36797
2010	36805
Munoz-Quiles et al. , 2009	36811
Munoz-Quiles	36811
et al. , 2009	36824
et al.	36824
2009	36832
Radtke and Wewetzer , 2009	36838
Radtke and Wewetzer	36838
2009	36859
reports from different laboratories	36875
reports	36875
different laboratories	36888
considerable variations	36929
results ranging from significant axonal regeneration across the lesion site and functional recovery -LRB- Gorrie et al. , 2010 ; Keyvan-Fouladi et al. , 2003 ; Lopez - Vales et al. , 2007 ; Ramon-Cueto et al. , 2000 ; Takeoka et al. , 2010 -RRB- to very little or no effect after spinal cord repair -LRB- Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006 -RRB-	36956
results	36956
significant axonal regeneration across the lesion site and functional recovery -LRB- Gorrie et al. , 2010 ; Keyvan-Fouladi et al. , 2003 ; Lopez - Vales et al. , 2007 ; Ramon-Cueto et al. , 2000 ; Takeoka et al. , 2010 -RRB- to very little or no effect after spinal cord repair -LRB- Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006 -RRB-	36977
significant axonal regeneration across the lesion site	36977
significant axonal regeneration	36977
the lesion site	37016
functional recovery -LRB- Gorrie et al. , 2010 ; Keyvan-Fouladi et al. , 2003 ; Lopez - Vales et al. , 2007 ; Ramon-Cueto et al. , 2000 ; Takeoka et al. , 2010 -RRB- to very little or no effect after spinal cord repair -LRB- Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006 -RRB-	37036
functional recovery	37036
Gorrie et al. , 2010 ; Keyvan-Fouladi et al. , 2003 ; Lopez - Vales et al. , 2007 ; Ramon-Cueto et al. , 2000 ; Takeoka et al. , 2010	37057
Gorrie	37057
et al. , 2010 ; Keyvan-Fouladi et al. , 2003 ; Lopez - Vales et al. , 2007 ; Ramon-Cueto et al. , 2000 ; Takeoka et al. , 2010	37064
et al. , 2010	37064
et al.	37064
2010	37072
Keyvan-Fouladi et al. , 2003	37078
Keyvan-Fouladi	37078
et al. , 2003	37093
et al.	37093
2003	37101
Lopez - Vales et al. , 2007	37107
Lopez	37107
Vales et al. , 2007	37114
Vales	37114
et al. , 2007	37120
et al.	37120
2007	37128
Ramon-Cueto et al. , 2000	37134
Ramon-Cueto	37134
et al. , 2000	37146
et al.	37146
2000	37154
Takeoka et al. , 2010	37160
Takeoka	37160
et al. , 2010	37168
et al.	37168
2010	37176
very little or no effect after spinal cord repair -LRB- Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006 -RRB-	37185
very little or no effect after spinal cord repair	37185
no effect after spinal cord	37200
no effect	37200
spinal cord	37216
Aoki et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006	37236
Aoki	37236
et al. , 2010 ; Barakat et al. , 2005 ; Bretzner et al. , 2010 ; Collazos-Castro et al. , 2005 ; Lu et al. , 2006 ; Steward et al. , 2006	37241
et al. , 2010	37241
et al.	37241
2010	37249
Barakat et al. , 2005	37255
Barakat	37255
et al. , 2005	37263
et al.	37263
2005	37271
Bretzner et al. , 2010	37277
Bretzner	37277
et al. , 2010	37286
et al.	37286
2010	37294
Collazos-Castro et al. , 2005	37300
Collazos-Castro	37300
et al. , 2005	37316
et al.	37316
2005	37324
Lu et al. , 2006	37330
Lu	37330
et al. , 2006	37333
et al.	37333
2006	37341
Steward et al. , 2006	37347
Steward	37347
et al. , 2006	37355
et al.	37355
2006	37363
The conflicting data regarding the ability of OEC to support axonal regeneration have been reviewed -LRB- Barnett and Riddell , 2007 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams , 2008 -RRB- and the factors which could potentially determine the outcome of OEC transplantation	37370
The conflicting data	37370
the ability of OEC to support axonal regeneration have been reviewed -LRB- Barnett and Riddell , 2007 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams , 2008 -RRB- and the factors which could potentially determine the outcome of OEC transplantation	37401
the ability	37401
OEC to support axonal regeneration have been reviewed -LRB- Barnett and Riddell , 2007 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams , 2008 -RRB- and the factors which could potentially determine the outcome of OEC transplantation	37416
OEC to support axonal regeneration have been reviewed -LRB- Barnett and Riddell , 2007 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams , 2008 -RRB-	37416
OEC	37416
axonal regeneration	37431
Barnett and Riddell , 2007 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams , 2008	37471
Barnett and Riddell	37471
2007 ; Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams	37492
2007	37492
Nieto-Sampedro , 2003 ; Raisman and Li , 2007 ; Richter and Roskams	37498
Nieto-Sampedro , 2003	37498
Nieto-Sampedro	37498
2003	37514
Raisman and Li , 2007	37520
Raisman and Li	37520
2007	37536
Richter and Roskams	37542
Richter	37542
Roskams	37554
2008	37563
the factors which could potentially determine the outcome of OEC transplantation	37573
the factors	37573
the outcome of OEC transplantation	37619
the outcome	37619
OEC transplantation	37634
there	37684
no consensus in the ongoing discussion about significance of these factors of importance for OEC transplantation into spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37693
no consensus	37693
the ongoing discussion about significance of these factors of importance for OEC transplantation into spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37709
the ongoing discussion	37709
significance of these factors of importance for OEC transplantation into spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37738
significance	37738
these factors of importance for OEC transplantation into spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37754
these factors	37754
importance for OEC transplantation into spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37771
importance	37771
OEC transplantation into spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37786
OEC transplantation	37786
spinal cord injury -LRB- Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006 -RRB-	37811
spinal cord injury	37811
Barnett and Riddell , 2007 ; Deumens et al. , 2006 ; Lu et al. , 2006	37831
Barnett and Riddell	37831
2007 ; Deumens et al. , 2006 ; Lu et al.	37852
2007	37852
Deumens et al. , 2006 ; Lu et al.	37858
Deumens	37858
et al. , 2006 ; Lu et al.	37866
et al. , 2006	37866
et al.	37866
2006	37874
Lu et al.	37880
Lu	37880
et al.	37883
2006	37891
the source of tissue used to obtain the OEC -LRB- neonatal and adult olfactory bulb and olfactory mucosa -RRB- , the senescence and the purity of transplanted cells and the methodology used in the culture preparation	37898
the source of tissue used to obtain the OEC -LRB- neonatal and adult olfactory bulb and olfactory mucosa -RRB-	37898
the source of tissue used to obtain the OEC	37898
the source	37898
tissue used to obtain the OEC	37912
tissue	37912
the OEC	37934
neonatal and adult	37943
olfactory bulb and olfactory mucosa	37962
olfactory bulb	37962
olfactory mucosa	37981
the senescence	38000
the purity of transplanted cells and the methodology used in the culture preparation	38019
the purity	38019
transplanted cells and the methodology used in the culture preparation	38033
transplanted cells	38033
the methodology used in the culture preparation	38056
the methodology	38056
the culture preparation	38080
the most important variables -LRB- Pastrana et al. , 2006 , 2007 ; Richter et al. , 2005 ; Santos - Benito and Ramon-Cueto , 2003 -RRB-	38115
the most important variables	38115
Pastrana	38145
et al. , 2006 , 2007 ; Richter et al. , 2005 ; Santos - Benito and Ramon-Cueto , 2003	38154
et al.	38154
2006 , 2007 ; Richter et al. , 2005 ; Santos - Benito and Ramon-Cueto	38162
2006 , 2007	38162
2006	38162
2007	38168
Richter et al. , 2005 ; Santos - Benito and Ramon-Cueto	38174
Richter	38174
et al. , 2005 ; Santos - Benito and Ramon-Cueto	38182
et al.	38182
2005	38190
Santos	38196
Benito	38204
Ramon-Cueto	38215
2003	38228
direct comparisons made in the same experimental model between differently composed cell grafts	38244
direct comparisons	38244
the same experimental model between differently composed cell grafts	38271
the same experimental model	38271
cell grafts	38328
the donor age , the purity of the cells and the presence of an endogenously produced matrix	38354
the donor age , the purity of the cells	38354
the donor age	38354
the purity of the cells	38369
the purity	38369
the cells	38383
the presence of an endogenously produced matrix	38397
the presence	38397
an endogenously produced matrix	38413
the discrepancy in results found in OEC transplant studies -LRB- Andrews and Stelzner , 2004 ; Deumens et al. , 2006 ; Toft et al. , 2007 -RRB-	38464
the discrepancy	38464
results found in OEC transplant studies -LRB- Andrews and Stelzner , 2004 ; Deumens et al. , 2006 ; Toft et al. , 2007 -RRB-	38483
results	38483
OEC transplant studies -LRB- Andrews and Stelzner , 2004 ; Deumens et al. , 2006 ; Toft et al. , 2007 -RRB-	38500
OEC transplant studies	38500
Andrews and Stelzner , 2004 ; Deumens et al. , 2006 ; Toft et al. , 2007	38524
Andrews and Stelzner	38524
2004 ; Deumens et al. , 2006 ; Toft et al.	38546
2004	38546
Deumens et al. , 2006 ; Toft et al.	38552
Deumens	38552
et al. , 2006 ; Toft et al.	38560
et al. , 2006	38560
et al.	38560
2006	38568
Toft et al.	38574
Toft	38574
et al.	38579
2007	38587
the initial findings that OEC from the lamina propria are more beneficial for spinal cord repair than the cells from the olfactory bulb -LRB- Richter et al. , 2005 -RRB-	38599
the initial findings that OEC from the lamina propria are more beneficial for spinal cord repair than the cells from the olfactory bulb	38599
the initial findings	38599
OEC from the lamina propria	38625
OEC	38625
the lamina propria	38634
spinal cord repair than the cells	38677
spinal cord repair	38677
the cells	38701
the olfactory bulb	38716
Richter	38736
et al. , 2005	38744
et al.	38744
2005	38752
a subsequent study -LRB- Lu et al. , 2006 -RRB-	38785
a subsequent study	38785
Lu	38805
et al. , 2006	38808
et al.	38808
2006	38816
studies dealing with demyelination in the rat and porcine spinal cord	38835
studies	38835
demyelination in the rat and porcine spinal cord	38856
demyelination	38856
the rat and porcine spinal cord	38873
it	38906
the purity of cell cultures and the senescence of OEC	38929
the purity of cell cultures	38929
the purity	38929
cell cultures	38943
the senescence of OEC	38961
the senescence	38961
OEC	38979
remyelination -LRB- Lakatos et al. , 2003 ; Radtke et al. , 2010 -RRB-	39013
remyelination	39013
Lakatos	39028
et al. , 2003 ; Radtke et al. , 2010	39036
et al.	39036
2003 ; Radtke et al.	39044
2003	39044
Radtke et al.	39050
Radtke	39050
et al.	39057
2010	39065
The results of the present study	39072
The results	39072
the present study	39087
previous observations that prolonged cell cultures reduce stimulatory effect of OEC and , in addition , demonstrate that the technique of cell purification could modulate growthpromoting effect of OEC after transplantation into spinal cord	39123
previous observations	39123
cell cultures	39160
stimulatory effect of OEC	39181
stimulatory effect	39181
OEC	39203
addition	39215
the technique of cell purification	39242
the technique	39242
cell purification	39259
growthpromoting effect of OEC	39292
growthpromoting effect	39292
OEC	39318
transplantation	39328
spinal cord	39349
Long-term cultured OEC	39362
Long-term	39362
OEC	39381
regeneration and neuronal survival The mechanisms underlying the lack of neurotrophic and growthpromoting effects of long-term cultured OEC are not clear	39403
regeneration and neuronal survival	39403
The mechanisms underlying the lack of neurotrophic and growthpromoting effects of long-term cultured OEC	39438
The mechanisms	39438
the lack of neurotrophic and growthpromoting effects of long-term cultured OEC	39464
the lack	39464
neurotrophic and growthpromoting effects of long-term cultured OEC	39476
neurotrophic and growthpromoting effects	39476
long-term cultured OEC	39520
long-term	39520
OEC	39539
They	39558
the low survival rate of transplanted OEC -LRB- Pearse et al. , 2007 -RRB-	39586
the low survival rate	39586
transplanted OEC -LRB- Pearse et al. , 2007 -RRB-	39611
transplanted OEC	39611
Pearse	39629
et al. , 2007	39636
et al.	39636
2007	39644
the loss of certain classes of surface receptors which are important for interaction with surrounding glial cells , macrophages and regenerating axons	39657
the loss	39657
certain classes of surface receptors	39669
certain classes	39669
surface receptors	39688
interaction	39730
surrounding glial cells , macrophages and regenerating axons	39747
surrounding glial cells	39747
macrophages	39772
regenerating axons	39788
this respect	39811
the results	39825
OEC	39856
their p75 immunoreactivity	39867
several months	39898
transplantation sited with long-term cultured OEC	39923
transplantation	39923
long-term cultured OEC	39950
long-term	39950
OEC	39969
lower levels of p75 expression	39978
lower levels	39978
p75 expression	39994
cells	40039
it	40052
contrast to primate OEC	40094
contrast	40094
primate OEC	40106
adult rat and porcine OEC	40119
adult rat	40119
porcine OEC	40133
3 -- 5 weeks in culture	40182
3	40182
5 weeks in culture	40184
5 weeks	40184
culture	40195
their phenotypic properties -LRB- Radtke et al. , 2010 ; Rubio et al. , 2008 -RRB-	40212
their phenotypic properties	40212
Radtke	40241
et al. , 2010 ; Rubio et al. , 2008	40248
et al.	40248
2010 ; Rubio et al.	40256
2010	40256
Rubio et al.	40262
Rubio	40262
et al.	40268
2008	40276
it	40293
culture period	40319
several weeks	40350
senescence	40371
OEC	40383
division	40398
spontaneous immortalization -LRB- Rubio et al. , 2008 ; Sonigra et al. , 1996 -RRB-	40419
spontaneous immortalization	40419
Rubio	40448
et al. , 2008 ; Sonigra et al. , 1996	40454
et al.	40454
2008 ; Sonigra et al.	40462
2008	40462
Sonigra et al.	40468
Sonigra	40468
et al.	40476
1996	40484
Another possible explanation	40491
the reports	40540
OEC	40557
several classes of neurotrophic molecules including NGF , NT-4 / 5 , BDNF and GDNF -LRB- Lipson et al. , 2003 ; Pastrana et al. , 2007 ; Sasaki et al. , 2006 -RRB- which are known to promote neuronal survival and axonal regeneration after spinal cord injury -LRB- Deumens et al. , 2005 -RRB- However , after prolonged time in culture OEC might stop to produce sufficient amounts of neurotrophic factors and lose their neuroprotective effect after intraspinal transplantation	40591
several classes of neurotrophic molecules including NGF , NT-4 / 5 , BDNF and GDNF	40591
several classes of neurotrophic molecules including NGF , NT-4	40591
several classes	40591
neurotrophic molecules including NGF , NT-4	40610
neurotrophic molecules	40610
NGF , NT-4	40643
NGF	40643
NT-4	40648
5 , BDNF and GDNF	40653
5	40653
BDNF and GDNF	40656
Lipson et al. , 2003 ; Pastrana et al. , 2007 ; Sasaki et al. , 2006	40671
Lipson	40671
et al. , 2003 ; Pastrana et al. , 2007 ; Sasaki et al. , 2006	40678
et al. , 2003	40678
et al.	40678
2003	40686
Pastrana et al. , 2007	40692
Pastrana	40692
et al. , 2007	40701
et al.	40701
2007	40709
Sasaki et al. , 2006	40715
Sasaki	40715
et al. , 2006	40722
et al.	40722
2006	40730
neuronal survival and axonal regeneration	40763
neuronal survival	40763
axonal regeneration	40785
spinal cord injury -LRB- Deumens et al. , 2005 -RRB-	40811
spinal cord injury	40811
Deumens	40831
et al. , 2005	40839
et al.	40839
2005	40847
prolonged time in culture OEC	40868
prolonged time	40868
culture OEC	40886
sufficient amounts of neurotrophic factors	40920
sufficient amounts	40920
neurotrophic factors	40942
their neuroprotective effect	40972
intraspinal transplantation	41007
This hypothesis	41036
findings that extracellular BDNF is produced in significant amounts by the early passage OEC whereas the neurotrophin is absent in the extracellular medium collected from the late passage cells -LRB- Pastrana et al. , 2007 -RRB-	41068
findings	41068
extracellular BDNF	41082
significant amounts	41116
the early passage OEC	41139
the neurotrophin	41169
the extracellular medium collected from the late passage cells -LRB- Pastrana et al. , 2007 -RRB-	41199
the extracellular medium	41199
the late passage cells -LRB- Pastrana et al. , 2007 -RRB-	41239
the late passage cells	41239
Pastrana	41263
et al. , 2007	41272
et al.	41272
2007	41280
long-term cultured OEC	41297
long-term	41297
OEC	41316
very low levels of matrix metalloproteinase-2 which seems to be an important modulator of OEC-mediated axonal regeneration -LRB- Pastrana et al. , 2006 -RRB-	41325
very low levels	41325
matrix metalloproteinase-2 which seems to be an important modulator of OEC-mediated axonal regeneration -LRB- Pastrana et al. , 2006 -RRB-	41344
matrix metalloproteinase-2	41344
an important modulator of OEC-mediated axonal regeneration	41389
an important modulator	41389
OEC-mediated axonal regeneration	41415
Pastrana	41449
et al. , 2006	41458
et al.	41458
2006	41466
The latter results	41473
line	41499
observations that long-term cultured OEC are less efficient in inducing neurite outgrowth in vitro -LRB- Au et al. , 2007 ; Pastrana et al. , 2006 , 2007 -RRB-	41509
observations	41509
long-term cultured OEC	41527
long-term	41527
OEC	41546
neurite outgrowth	41581
Au et al. , 2007 ; Pastrana et al. , 2006 , 2007	41609
Au et al.	41609
Au	41609
et al.	41612
2007 ; Pastrana et al.	41620
2007	41620
Pastrana et al.	41626
Pastrana	41626
et al.	41635
2006 , 2007	41643
2006	41643
2007	41649
a new growth-promoting factor , the SPARC -LRB- secreted protein acidic rich in cystein -RRB- -LRB- osteonectin -RRB- ,	41665
a new growth-promoting factor	41665
the SPARC -LRB- secreted protein acidic rich in cystein -RRB- -LRB- osteonectin -RRB-	41696
the SPARC -LRB- secreted protein acidic rich in cystein -RRB-	41696
the SPARC	41696
protein acidic rich	41716
protein	41716
cystein	41739
osteonectin	41749
OEC conditioned medium -LRB- Au et al. , 2007 -RRB-	41786
OEC conditioned medium	41786
Au	41810
et al. , 2007	41813
et al.	41813
2007	41821
It	41828
SPARC	41858
an OEC-derived matricellular protein which could indirectly enhance the ability of Schwann cells to stimulate axonal regeneration via laminin-1 and TGFβ signaling	41867
an OEC-derived matricellular protein	41867
the ability of Schwann cells	41935
the ability	41935
Schwann cells	41950
axonal regeneration via laminin-1 and TGFβ signaling	41977
axonal regeneration	41977
laminin-1 and TGFβ signaling	42001
it	42040
early P2 passage OEC	42068
30 -- 50 % higher levels of SPARC expression than late P6 passage cells -LRB- Au et al. , 2007 -RRB-	42094
30	42094
50 % higher levels of SPARC expression than late P6 passage cells -LRB- Au et al. , 2007 -RRB-	42097
50 % higher levels	42097
SPARC expression than late P6 passage cells -LRB- Au et al. , 2007 -RRB-	42118
SPARC expression	42118
late P6 passage cells -LRB- Au et al. , 2007 -RRB-	42140
late P6 passage cells	42140
Au	42163
et al. , 2007	42166
et al.	42166
2007	42174
respect to neuroprotective effect of the short-term cultured OEC	42186
respect	42186
neuroprotective effect of the short-term cultured OEC	42197
neuroprotective effect	42197
the short-term cultured OEC	42223
the short-term	42223
OEC	42247
our findings	42252
line with previous reports	42272
line	42272
previous reports	42282
OEC transplantation into the injured spinal cord	42304
OEC transplantation	42304
the injured spinal cord	42329
corticospinal neurons	42378
retrograde degeneration -LRB- Sasaki et al. , 2006 -RRB-	42405
retrograde degeneration	42405
Sasaki	42430
et al. , 2006	42437
et al.	42437
2006	42445
Biochemical analysis performed in the latter study	42452
Biochemical analysis	42452
the latter study	42486
levels of BDNF	42538
levels	42538
BDNF	42548
the spinal cord injury zone	42556
1 week after OEC transplantation	42587
1 week	42587
OEC transplantation	42600
no difference	42624
NGF and NT-3 levels	42653
olfactory neural progenitors from the olfactory mucosa , with the capacity to generate both neurons and OEC ,	42684
olfactory neural progenitors	42684
the olfactory mucosa	42718
the capacity to generate both neurons and OEC	42745
both neurons and OEC	42770
neurons	42775
OEC	42787
BDNF	42819
red nucleus neurons	42849
SCI -LRB- Xiao et al. , 2005 -RRB-	42875
SCI	42875
Xiao	42880
et al. , 2005	42885
et al.	42885
2005	42893
It	42900
neurotrophic factors	42934
retrograde degeneration	42978
regeneration of rubrospinal neurons in different models of spinal cord injury -LRB- Kobayashi et al. , 1997 ; Novikova et al. , 2000 ; Storer et al. , 2003 ; Tobias et al. , 2003 -RRB-	43019
regeneration	43019
rubrospinal neurons in different models of spinal cord injury -LRB- Kobayashi et al. , 1997 ; Novikova et al. , 2000 ; Storer et al. , 2003 ; Tobias et al. , 2003 -RRB-	43035
rubrospinal neurons	43035
different models of spinal cord injury -LRB- Kobayashi et al. , 1997 ; Novikova et al. , 2000 ; Storer et al. , 2003 ; Tobias et al. , 2003 -RRB-	43058
different models	43058
spinal cord injury -LRB- Kobayashi et al. , 1997 ; Novikova et al. , 2000 ; Storer et al. , 2003 ; Tobias et al. , 2003 -RRB-	43078
spinal cord injury	43078
Kobayashi et al. , 1997 ; Novikova et al. , 2000 ; Storer et al. , 2003 ; Tobias et al. , 2003	43098
Kobayashi	43098
et al. , 1997 ; Novikova et al. , 2000 ; Storer et al. , 2003 ; Tobias et al. , 2003	43108
et al. , 1997	43108
et al.	43108
1997	43116
Novikova et al. , 2000	43122
Novikova	43122
et al. , 2000	43131
et al.	43131
2000	43139
Storer et al. , 2003	43145
Storer	43145
et al. , 2003	43152
et al.	43152
2003	43160
Tobias et al. , 2003	43166
Tobias	43166
et al. , 2003	43173
et al.	43173
2003	43181
varying outcomes of rubrospinal regeneration	43197
varying outcomes	43197
rubrospinal regeneration	43217
OEC transplantation	43267
complete spinal cord transection -LRB- Cao et al. , 2004 -RRB- or moderate contusion injury -LRB- Plant et al. , 2003 -RRB-	43298
complete spinal cord transection -LRB- Cao et al. , 2004 -RRB-	43298
complete spinal cord transection	43298
Cao	43332
et al. , 2004	43336
et al.	43336
2004	43344
moderate contusion injury -LRB- Plant et al. , 2003 -RRB-	43353
moderate contusion injury	43353
Plant	43380
et al. , 2003	43386
et al.	43386
2003	43394
significant increase in the number of retrogradely labeled neurons	43401
significant increase	43401
the number of retrogradely labeled neurons	43425
the number	43425
retrogradely labeled neurons	43439
the red nucleus	43487
The present study	43504
growth-promoting effect of short-term cultured a-OEC on rubrospinal neurons	43540
growth-promoting effect	43540
short-term cultured a-OEC on rubrospinal neurons	43567
short-term	43567
a-OEC	43587
rubrospinal neurons	43596
contrast	43620
less-severe injury to the dorsolateral funiculus	43636
less-severe injury	43636
the dorsolateral funiculus	43658
anterograde tracing	43686
anterograde	43686
no regeneration of rubrospinal axons across the lesion site	43714
no regeneration	43714
rubrospinal axons across the lesion site	43733
rubrospinal axons	43733
the lesion site	43758
the distal cord -LRB- Bretzner et al. , 2010 ; Ruitenberg et al. , 2003 -RRB-	43779
the distal cord	43779
Bretzner	43796
et al. , 2010 ; Ruitenberg et al. , 2003	43805
et al.	43805
2010 ; Ruitenberg et al.	43813
2010	43813
Ruitenberg et al.	43819
Ruitenberg	43819
et al.	43830
2003	43838
Method of cell purification	43845
Method	43845
cell purification	43855
growth-promoting effect of OEC transplant The limited effects of b-OEC on regeneration were unexpected because it has been previously shown that the same method of purification with immunomagnetic Dynabeads results in OEC grafts capable of inducing significant regenerative response after transplantation into completely transected rat spinal cord -LRB- Lopez-Vales et al. , 2006 , 2007 -RRB-	43886
growth-promoting effect	43886
OEC transplant	43913
The limited effects of b-OEC on regeneration	43928
The limited effects	43928
b-OEC on regeneration	43951
b-OEC	43951
regeneration	43960
it	43997
the same method of purification with immunomagnetic Dynabeads	44031
the same method	44031
purification with immunomagnetic Dynabeads	44050
purification	44050
immunomagnetic Dynabeads	44068
OEC grafts capable of inducing significant regenerative response after transplantation	44104
OEC grafts	44104
significant regenerative response	44135
transplantation	44175
rat spinal cord -LRB- Lopez-Vales et al. , 2006 , 2007 -RRB-	44218
rat spinal cord	44218
Lopez-Vales	44235
et al. , 2006 , 2007	44247
et al.	44247
2006	44255
2007	44261
immunomagnetic beads separate only OEC with sufficiently strong expression of p75 receptors	44277
immunomagnetic beads separate only OEC	44277
immunomagnetic beads	44277
separate only OEC	44298
sufficiently strong expression of p75 receptors	44321
sufficiently strong expression	44321
p75 receptors	44355
all other OEC subtypes	44377
the supernatant	44403
It	44420
the major OEC population in primary cells suspensions	44455
the major OEC population	44455
primary cells suspensions	44483
p75 receptors	44536
them	44566
several days in culture -LRB- Wewetzer et al. , 2005 -RRB-	44577
several days	44577
culture -LRB- Wewetzer et al. , 2005 -RRB-	44593
culture	44593
Wewetzer	44602
et al. , 2005	44611
et al.	44611
2005	44619
it	44632
contrast to previous reports -LRB- Lopez-Vales et al. , 2006 , 2007 -RRB-	44655
contrast	44655
previous reports -LRB- Lopez-Vales et al. , 2006 , 2007 -RRB-	44667
previous reports	44667
Lopez-Vales	44685
et al. , 2006 , 2007	44697
et al.	44697
2006	44705
2007	44711
we	44718
different subtypes of OEC which had marked neuroprotective effect	44731
different subtypes	44731
OEC	44753
neuroprotective effect	44774
axonal regrowth	44819
Another possibility	44836
the cell surface Dynabeads could interfere with the processes of interaction between transplanted OEC	44877
the cell	44877
surface Dynabeads	44886
the processes of interaction between transplanted OEC	44925
the processes	44925
interaction between transplanted OEC	44942
interaction	44942
transplanted OEC	44962
host cells including reactive astrocytes	44995
host cells	44995
reactive astrocytes	45016
it	45046
short-term cultured a-OEC	45066
short-term	45066
a-OEC	45086
rubrospinal neurons	45123
b-OEC	45148
axonal regrowth	45197
the trauma zone	45220
One possibility	45237
the signaling pathways promoting neuronal survival and axonal regeneration	45261
the signaling pathways	45261
neuronal survival and axonal regeneration	45294
neuronal survival	45294
axonal regeneration	45316
neurotrophic factors	45359
efficient neuroprotection of axotomized neurons	45389
efficient neuroprotection	45389
neurons	45429
a sufficient prerequisite for axonal regeneration -LRB- Lu et al. , 2001 ; Novikova et al. , 2002 -RRB-	45444
a sufficient prerequisite	45444
axonal regeneration -LRB- Lu et al. , 2001 ; Novikova et al. , 2002 -RRB-	45474
axonal regeneration	45474
Lu	45495
et al. , 2001 ; Novikova et al. , 2002	45498
et al.	45498
2001 ; Novikova et al.	45506
2001	45506
Novikova et al.	45512
Novikova	45512
et al.	45521
2002	45529
Another interesting observation in the present study	45536
Another interesting observation	45536
the present study	45571
the neuroprotective effect of the short-term cultured OEC	45597
the neuroprotective effect	45597
the short-term cultured OEC	45627
the short-term	45627
OEC	45651
rubrospinal sprouting	45682
rubrospinal	45682
The same effects on lesioned rubrospinal neurons	45705
The same effects	45705
lesioned rubrospinal neurons	45725
prolonged intrathecal infusion of BDNF and NT-3 -LRB- Novikova et al. , 2002 -RRB-	45791
prolonged intrathecal infusion	45791
BDNF and NT-3 -LRB- Novikova et al. , 2002 -RRB-	45825
BDNF and NT-3	45825
Novikova	45840
et al. , 2002	45849
et al.	45849
2002	45857
summary	45867
the present study	45876
the age of cells in culture and the method of cell purification	45912
the age	45912
cells in culture and the method of cell purification	45923
cells in culture	45923
cells	45923
culture	45932
the method of cell purification	45944
the method	45944
cell purification	45958
influence on the growth-promoting and neuroprotective effects of OEC after transplantation	45981
influence	45981
the growth-promoting and neuroprotective effects of OEC after transplantation	45994
the growth-promoting and neuroprotective effects	45994
OEC after transplantation	46046
OEC	46046
transplantation	46056
the injured spinal cord	46077
The finding that methods of culture preparation might affect the outcome of OEC transplantation	46102
The finding	46102
methods of culture preparation	46119
methods	46119
culture preparation	46130
the outcome of OEC transplantation	46163
the outcome	46163
OEC transplantation	46178
an important issue	46207
human trials with OEC	46232
human trials	46232
OEC	46250
several countries -LRB- Dobkin et al. , 2006 ; Kay-Sim et al. , 2008 -RRB-	46277
several countries	46277
Dobkin	46296
et al. , 2006 ; Kay-Sim et al. , 2008	46303
et al.	46303
2006 ; Kay-Sim et al.	46311
2006	46311
Kay-Sim et al.	46317
Kay-Sim	46317
et al.	46325
2008	46333
